https://www.pharmaradar360.com hourly 1 https://www.pharmaradar360.com/news hourly 0.95 https://www.pharmaradar360.com/regulators daily 0.9 https://www.pharmaradar360.com/trials daily 0.85 https://www.pharmaradar360.com/pipeline daily 0.9 https://www.pharmaradar360.com/drug-approvals daily 0.9 https://www.pharmaradar360.com/journals weekly 0.8 https://www.pharmaradar360.com/pharma-companies weekly 0.8 https://www.pharmaradar360.com/specialties weekly 0.8 https://www.pharmaradar360.com/sources weekly 0.8 https://www.pharmaradar360.com/newsrooms weekly 0.8 https://www.pharmaradar360.com/pharma-tools weekly 0.8 https://www.pharmaradar360.com/pharma-communities weekly 0.75 https://www.pharmaradar360.com/pro weekly 0.75 https://www.pharmaradar360.com/tools weekly 0.7 https://www.pharmaradar360.com/about monthly 0.5 https://www.pharmaradar360.com/privacy yearly 0.35 https://www.pharmaradar360.com/support monthly 0.35 https://www.pharmaradar360.com/disclaimer yearly 0.35 https://www.pharmaradar360.com/drug/pembrolizumab daily 0.9 https://www.pharmaradar360.com/drug/semaglutide daily 0.9 https://www.pharmaradar360.com/drug/tirzepatide daily 0.9 https://www.pharmaradar360.com/drug/trastuzumab-deruxtecan daily 0.9 https://www.pharmaradar360.com/drug/osimertinib daily 0.9 https://www.pharmaradar360.com/drug/nivolumab daily 0.9 https://www.pharmaradar360.com/drug/dupilumab daily 0.9 https://www.pharmaradar360.com/drug/risankizumab daily 0.9 https://www.pharmaradar360.com/drug/lecanemab daily 0.9 https://www.pharmaradar360.com/drug/atezolizumab daily 0.9 https://www.pharmaradar360.com/article/promising-biotech-stocks-to-follow-today-september-14th-ef83ca4efd667b1b 2026-09-14T16:04:48.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-path-to-stability-at-fda-188b02c94a11daad 2026-09-14T15:56:05.000Z weekly 0.7 https://www.pharmaradar360.com/article/extracting-cbd-from-artisanal-practice-to-industrial-production-ccc31add2fafeeeb 2026-09-14T15:51:14.000Z weekly 0.7 https://www.pharmaradar360.com/article/rtw-biotech-opportunities-ltd-reports-earnings-results-for-the-half-year-ended-j-da34acb47d55b873 2026-09-14T15:50:27.000Z weekly 0.7 https://www.pharmaradar360.com/article/pds-biotech-announces-initial-closing-of-up-to-22-3-mln-pipe-financing-b6b99a80672f80c4 2026-09-14T15:37:09.000Z weekly 0.7 https://www.pharmaradar360.com/article/is-krystal-biotech-krys-cheap-on-its-cantor-conference-spotlight-0c18fece4209bc40 2026-09-14T15:34:25.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-places-partial-clinical-hold-on-biohaven-s-epilepsy-drug-days-after-795-mill-fb310141e51e479d 2026-09-14T15:29:22.000Z weekly 0.7 https://www.pharmaradar360.com/article/no-more-nordisk-novo-s-latest-trim-is-in-its-name-ac18f90a0e95918d 2026-09-14T15:22:30.000Z weekly 0.7 https://www.pharmaradar360.com/article/cover-of-vaccination-evaluated-rapidly-cover-programme-2026-to-2027-quarterly-da-854a7f00c802afc8 2026-09-14T15:13:36.000Z weekly 0.7 https://www.pharmaradar360.com/article/dhsc-public-appointments-2026-to-2027-92f3e9c4047ba1dc 2026-09-14T15:10:17.000Z weekly 0.7 https://www.pharmaradar360.com/article/new-haven-biotech-seeks-to-raise-150m-for-drug-development-93d25e67402257ae 2026-09-14T15:07:43.000Z weekly 0.7 https://www.pharmaradar360.com/article/midcap-biotech-outlook-cmps-leads-on-trend-momentum-and-catalyst-timing-9644863c7fee914b 2026-09-14T15:02:42.000Z weekly 0.7 https://www.pharmaradar360.com/article/2025-2025-bb92cb39bafb6027 2026-09-14T15:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/dengue-the-green-book-chapter-d659d5bcdd75ad40 2026-09-14T14:52:11.000Z weekly 0.7 https://www.pharmaradar360.com/article/us-fda-grants-priority-review-to-zasocitinib-for-moderate-to-severe-pso-1e9daa76b6caf233 2026-09-14T14:50:59.000Z weekly 0.7 https://www.pharmaradar360.com/article/pds-biotech-announces-initial-closing-of-up-to-22-3-million-pipe-financing-and-t-ca8e381455767ccd 2026-09-14T14:43:10.000Z weekly 0.7 https://www.pharmaradar360.com/article/pds-biotechnology-raises-11-3-million-in-initial-closing-of-pipe-led-by-nant-cap-920b0390e9a9b55d 2026-09-14T14:40:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/uk-covid-19-inquiry-53a03ab2ca904c16 2026-09-14T14:36:59.000Z weekly 0.7 https://www.pharmaradar360.com/article/uk-government-response-to-the-covid-19-inquiry-module-3-report-82255ac20476e0dc 2026-09-14T14:36:34.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-cancer-biotech-raises-11-3-million-the-los-angeles-times-owner-joins-its-board-36c5c0123605f906 2026-09-14T14:30:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/definium-therapeutics-dftx-stock-soars-20-on-successful-phase-3-anxiety-trial-re-b93947691e55d7f8 2026-09-14T14:23:30.000Z weekly 0.7 https://www.pharmaradar360.com/article/nifst-stakeholders-seek-evidence-based-regulation-of-low-calorie-sweeteners-85989083eb27fcb7 2026-09-14T14:12:18.000Z weekly 0.7 https://www.pharmaradar360.com/article/biomarin-pharmaceutical-appoints-robert-plenge-to-board-of-directors-b4f7261b09af2577 2026-09-14T14:09:12.000Z weekly 0.7 https://www.pharmaradar360.com/article/immunocore-achieves-full-enrollment-in-phase-3-tebe-am-melanoma-study-16e530c8f0b3f5f0 2026-09-14T14:02:17.000Z weekly 0.7 https://www.pharmaradar360.com/article/rezilient3-trial-efficacy-and-safety-data-of-zipalertinib-in-egfr-exon-20-insert-781f2e368253f241 2026-09-14T14:01:50.000Z weekly 0.7 https://www.pharmaradar360.com/article/recce-pharmaceuticals-asx-rce-phase-3-diabetic-foot-infection-trial-and-mena-lic-38124a0b87aac230 2026-09-14T13:58:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/positive-topline-results-from-phase-3-panorama-study-of-dt120-odt-in-generalized-e256990a7d983a8b 2026-09-14T13:54:36.000Z weekly 0.7 https://www.pharmaradar360.com/article/veraxa-biotech-vrxa-insider-trading-activity-2026-249623a1453a3bf2 2026-09-14T13:48:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/gsk-touts-lung-cancer-data-from-two-drugs-8d677a7a22389a58 2026-09-14T13:38:49.000Z weekly 0.7 https://www.pharmaradar360.com/article/biotech-growth-trust-extends-strong-performance-in-2026-d9b4635f68450caa 2026-09-14T13:32:34.000Z weekly 0.7 https://www.pharmaradar360.com/article/sahpra-and-lesotho-strengthen-regional-collaboration-for-regulatory-excellence-45f1f401fec36a52 2026-09-14T13:23:20.000Z weekly 0.7 https://www.pharmaradar360.com/article/west-pharmaceutical-services-at-morgan-stanley-conference-growth-broadens-fe0c6b0b57907f44 2026-09-14T13:19:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/exclusive-dr-michael-c-burgess-we-need-a-new-playbook-to-guard-against-counterfe-6956c7305798f01d 2026-09-14T13:09:44.000Z weekly 0.7 https://www.pharmaradar360.com/article/sex-ratios-at-birth-in-the-uk-2019-to-2023-800293e4e71f3202 2026-09-14T13:05:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/biomarin-pharmaceutical-inc-nasdaq-bmrn-appoints-bms-r-d-chief-robert-plenge-to-d11aa567c7551aa2 2026-09-14T13:05:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/rabies-post-exposure-risk-assessment-d5bf37390bb160f1 2026-09-14T13:00:02.000Z weekly 0.7 https://www.pharmaradar360.com/article/krtl-biotech-appoints-federal-controlled-substance-compliance-specialist-justin-4350832aa88145f3 2026-09-14T13:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/dare-bioscience-announces-peer-reviewed-publication-of-phase-1-sildenafil-cream-05d0eae494a7f684 2026-09-14T12:59:26.000Z weekly 0.7 https://www.pharmaradar360.com/article/organon-announces-us-fda-has-accepted-for-review-a-supplemental-new-drug-applica-6c0c0422506d902f 2026-09-14T12:57:01.000Z weekly 0.7 https://www.pharmaradar360.com/article/electra-aims-for-342m-ipo-to-power-inflammatory-drug-s-push-through-phase-3-0240e717903fd159 2026-09-14T12:52:57.000Z weekly 0.7 https://www.pharmaradar360.com/article/5-small-drug-stocks-poised-to-benefit-from-a-biotech-recovery-570bf916e68b800a 2026-09-14T12:51:01.000Z weekly 0.7 https://www.pharmaradar360.com/article/j-j-looking-to-offload-orthopedics-unit-in-20b-deal-to-apollo-bloomberg-dc98416c34c5142a 2026-09-14T12:40:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/gatc-health-joins-critical-path-institute-s-new-approach-methodologies-developer-05166a46c1038966 2026-09-14T12:38:47.000Z weekly 0.7 https://www.pharmaradar360.com/article/cardiff-oncology-and-nerviano-medical-sciences-amend-their-2017-exclusive-licens-5715a4c53623c959 2026-09-14T12:38:44.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-biotech-growth-trust-plc-monthly-fact-sheet-as-at-31-august-2026-a063b8d62d709d23 2026-09-14T12:38:08.000Z weekly 0.7 https://www.pharmaradar360.com/article/etra-ipo-news-antibody-biotech-electra-therapeutics-sets-terms-for-325-million-i-0ecc46d14794d0ab 2026-09-14T12:37:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/geovax-and-cepi-enter-agreement-to-utilize-cepi-centralised-laboratory-network-t-68dec5d4551f2cf9 2026-09-14T12:37:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/global-cancer-drug-rights-dispute-settled-by-cardiff-and-nerviano-21e0f50be19d2e22 2026-09-14T12:30:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/acto-named-among-everest-group-s-top-50tm-pharmaceutical-technology-providers-fo-cc8fcd1bfda5c382 2026-09-14T12:30:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/biontech-nasdaq-bntx-lung-cancer-drug-extends-survival-vs-chemo-in-phase-3-c6832e849c4d7d59 2026-09-14T12:29:11.000Z weekly 0.7 https://www.pharmaradar360.com/article/major-shift-in-biotech-manufacturing-canva-0f67a9758151f283 2026-09-14T12:28:08.000Z weekly 0.7 https://www.pharmaradar360.com/article/leios-therapeutics-announces-positive-end-of-phase-2-meeting-with-fda-for-10xb-1-573671facadcb78f 2026-09-14T12:17:30.000Z weekly 0.7 https://www.pharmaradar360.com/article/cancer-and-autoimmune-trials-define-legend-biotech-legn-cell-therapy-pipeline-e925d7051366c5a6 2026-09-14T12:09:14.000Z weekly 0.7 https://www.pharmaradar360.com/article/briacell-bctx-phase-3-trial-safety-endorsement-highlights-market-s-cautious-outl-2ca36055c44df42a 2026-09-14T12:09:13.000Z weekly 0.7 https://www.pharmaradar360.com/article/data-safety-monitoring-board-recommends-continuing-briacell-s-phase-3-metastatic-00b5e7c605eb755f 2026-09-14T12:01:27.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-48-hour-home-treatment-for-postpartum-depression-enters-a-new-study-about-120-6e444e94543dfa0a 2026-09-14T12:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/sls-stock-slumps-as-legal-scrutiny-hits-phase-3-trial-1f83efc08a3e0313 2026-09-14T11:47:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/maharashtra-food-and-drug-administration-seizes-unsafe-dairy-products-e5136b5fcb9275cd 2026-09-14T11:43:22.000Z weekly 0.7 https://www.pharmaradar360.com/article/etf-movement-china-asset-management-hang-seng-biotech-etf-03069-surges-over-4-am-2b7d5a6e5fdce085 2026-09-14T11:34:43.000Z weekly 0.7 https://www.pharmaradar360.com/article/medtronic-launches-exchange-offer-to-complete-separation-of-minimed-group-inc-e382312e420e5aaa 2026-09-14T11:30:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-breast-cancer-trial-gets-a-seventh-recommendation-to-continue-5b0431d8e7492c3c 2026-09-14T11:30:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/field-safety-notices-7-september-to-11-september-2026-593a20d84f2235c2 2026-09-14T11:25:18.000Z weekly 0.7 https://www.pharmaradar360.com/article/biomarin-pharmaceutical-nasdaq-bmrn-forms-tight-breakout-setup-with-strong-techn-8e3a96b30e8b630e 2026-09-14T11:20:40.000Z weekly 0.7 https://www.pharmaradar360.com/article/pharmazz-inc-receives-u-s-fda-orphan-drug-designation-for-sovateltide-for-the-tr-a207e4ccbfb768c7 2026-09-14T11:15:23.000Z weekly 0.7 https://www.pharmaradar360.com/article/immunocore-announces-target-enrollment-achieved-in-phase-3-tebe-am-trial-of-kimm-23a53a59beab5bbe 2026-09-14T11:12:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/an-anxiety-treatment-met-every-key-goal-in-a-late-stage-trial-an-fda-meeting-is-0e9b1cfebc675f16 2026-09-14T11:02:53.000Z weekly 0.7 https://www.pharmaradar360.com/article/nmn-2026-9-14-ceda7cee25400dc0 2026-09-14T11:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/israeli-ag-biotech-company-plans-north-american-headquarters-in-indiana-4a390f206c0be123 2026-09-14T11:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/definium-therapeutics-announces-positive-topline-results-from-phase-3-panorama-s-2905618d20aa212a 2026-09-14T11:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/west-pharmaceutical-stock-holds-near-highs-after-strong-quarterly-beat-and-fresh-a94b2b2446bb6792 2026-09-14T10:57:20.000Z weekly 0.7 https://www.pharmaradar360.com/article/definium-lsd-drug-goes-3-for-3-with-another-pivotal-trial-win-fdd1cdfaac12bcca 2026-09-14T10:57:18.000Z weekly 0.7 https://www.pharmaradar360.com/article/scholar-rock-s-muscle-targeting-sma-therapy-isemblyd-lands-fda-approval-0c43d37e656f57b8 2026-09-14T10:50:12.000Z weekly 0.7 https://www.pharmaradar360.com/article/best-income-stocks-to-buy-for-september-14th-8c2cf2061f8628db 2026-09-14T10:44:43.000Z weekly 0.7 https://www.pharmaradar360.com/article/stifel-cuts-olema-pharmaceuticals-price-target-on-trial-concerns-0d5c9b3f2acc7cac 2026-09-14T10:42:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/lonza-deepens-us-bet-with-commercial-plant-in-oregon-a29a78ec68bd0365 2026-09-14T10:40:41.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-approves-telix-s-brain-cancer-imaging-drug-pixclara-449ed5b34cc35511 2026-09-14T10:34:27.000Z weekly 0.7 https://www.pharmaradar360.com/article/u-s-fda-accepts-new-drug-application-under-priority-review-for-takeda-s-zasociti-66c11273bfee998e 2026-09-14T10:31:50.000Z weekly 0.7 https://www.pharmaradar360.com/article/alcon-warns-that-us-proposal-could-cause-companies-to-abandon-europe-53d56b7bd75bdab8 2026-09-14T10:31:32.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-fda-s-proposed-drug-ad-rule-is-a-blueprint-for-violating-the-first-amendment-7fa4cc4a983c3d2f 2026-09-14T10:30:39.000Z weekly 0.7 https://www.pharmaradar360.com/article/first-in-human-clinical-trial-attacks-pancreatic-cancer-with-laser-light-50201537c62719b8 2026-09-14T10:30:36.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-grants-priority-review-to-takeda-nyse-tak-pill-for-severe-psoriasis-d7295820babd3de5 2026-09-14T10:26:20.000Z weekly 0.7 https://www.pharmaradar360.com/article/merck-provides-keytruda-at-no-cost-for-a-cancer-trial-7d3d50d0d822e36e 2026-09-14T10:16:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/morocco-s-pharmaceutical-trade-deficit-to-reach-1-4-billion-by-2030-9d175f14f5356cfb 2026-09-14T10:10:55.000Z weekly 0.7 https://www.pharmaradar360.com/article/speaker-fees-and-buy-and-bill-keep-doctors-loyal-to-pharma-0bcba66a606f3cfa 2026-09-14T10:09:13.000Z weekly 0.7 https://www.pharmaradar360.com/article/why-fragmented-contract-processes-are-slowing-pharmaceutical-operations-cd7413f3e757257d 2026-09-14T10:06:49.000Z weekly 0.7 https://www.pharmaradar360.com/article/could-western-mass-be-to-food-s-future-what-boston-is-to-biotech-umass-is-bettin-6f37059da1382faf 2026-09-14T10:03:41.000Z weekly 0.7 https://www.pharmaradar360.com/article/pharmaceutical-industry-corruption-is-structural-systemic-and-profitable-new-rev-b115c9249c53f64e 2026-09-14T10:00:06.000Z weekly 0.7 https://www.pharmaradar360.com/article/rtw-biotech-makes-16-5-half-year-return-as-surge-in-listed-drug-developers-outwe-edb7b30944ab4575 2026-09-14T09:54:09.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-fourth-ukrainian-pharmaceutical-warehouse-has-burned-in-a-russian-strike-since-6eb47225c106b55a 2026-09-14T09:41:41.000Z weekly 0.7 https://www.pharmaradar360.com/article/what-supplement-formulators-can-borrow-from-pharmaceutical-delivery-science-f3579b8398254e3c 2026-09-14T09:39:35.000Z weekly 0.7 https://www.pharmaradar360.com/article/pm-stresses-strengthening-egypt-s-pharmaceutical-industry-regulatory-system-8e45ce9f3a140f23 2026-09-14T09:33:13.000Z weekly 0.7 https://www.pharmaradar360.com/article/rtw-biotech-opportunities-ltd-2026-q2-results-earnings-call-presentation-otcmkts-fcb651dd64e3d3c2 2026-09-14T09:31:37.000Z weekly 0.7 https://www.pharmaradar360.com/article/gotistobart-nearly-doubles-survival-in-pretreated-squamous-lung-cancer-838a3314261d298d 2026-09-14T09:29:21.000Z weekly 0.7 https://www.pharmaradar360.com/article/trump-s-drug-policy-may-raise-south-korea-prices-57fd68f8da342994 2026-09-14T09:24:47.000Z weekly 0.7 https://www.pharmaradar360.com/article/ganpati-prasad-under-fda-watch-maharashtra-societies-told-to-follow-new-food-saf-630ea4175c9525b9 2026-09-14T09:21:37.000Z weekly 0.7 https://www.pharmaradar360.com/article/scholar-rock-wins-fda-approval-for-isembyld-6fd7f56f5e278d83 2026-09-14T09:18:51.000Z weekly 0.7 https://www.pharmaradar360.com/article/designing-the-exit-ip-strategy-for-venture-backed-biotech-patent-united-kingdom-90eb104909dcff8f 2026-09-14T09:13:04.000Z weekly 0.7 https://www.pharmaradar360.com/article/act-align-accelerate-europe-s-biotech-turning-point-aad0b26991fea488 2026-09-14T09:03:59.000Z weekly 0.7 https://www.pharmaradar360.com/article/spain-pushes-eu-wide-market-access-toolbox-for-innovative-biotech-medicines-830f72c452b45ef1 2026-09-14T09:01:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/china-has-a-chokehold-on-your-medicine-cabinet-it-s-a-national-security-threat-b390c227c0199626 2026-09-14T09:00:01.000Z weekly 0.7 https://www.pharmaradar360.com/article/hong-kong-stocks-rise-on-monday-on-tech-biotech-gains-trigiant-jumps-47-98c47dac2ec6c611 2026-09-14T08:45:38.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-prefix-is-no-shield-against-confusion-delhi-high-court-protects-biochem-eb4e0aa061fc398a 2026-09-14T08:31:34.000Z weekly 0.7 https://www.pharmaradar360.com/article/biontech-says-lung-cancer-drug-candidate-prolonged-lives-in-trial-bb6ddfdd81a51991 2026-09-14T08:31:19.000Z weekly 0.7 https://www.pharmaradar360.com/article/uk-clinical-research-delivery-key-performance-indicators-data-to-august-2026-1b10eeb5524e0803 2026-09-14T08:31:11.000Z weekly 0.7 https://www.pharmaradar360.com/article/biontech-says-lung-cancer-drug-candidate-prolonged-lives-in-trial-048c025d7109ee38 2026-09-14T08:30:37.000Z weekly 0.7 https://www.pharmaradar360.com/article/uk-clinical-research-delivery-key-performance-indicators-data-to-september-2026-72c636c8940d0e12 2026-09-14T08:29:48.000Z weekly 0.7 https://www.pharmaradar360.com/article/novo-will-adapt-to-the-changing-healthcare-market-with-a-new-visual-identity-f1df41c04eb14b89 2026-09-14T08:29:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/how-trump-s-pharmaceutical-plan-threatens-europe-higher-drug-prices-and-delays-i-50b78795a90ba91a 2026-09-14T08:20:57.000Z weekly 0.7 https://www.pharmaradar360.com/article/russia-strikes-fourth-ukrainian-pharmaceutical-warehouse-in-september-video-ed18c40308c28339 2026-09-14T08:16:14.000Z weekly 0.7 https://www.pharmaradar360.com/article/biontech-and-oncoc4-report-updated-phase-3-data-showing-gotistobart-nearly-doubl-32e2f4d485c7d29e 2026-09-14T08:10:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/taiho-pharmaceutical-co-ltd-taiho-oncology-inc-and-cullinan-therapeutics-inc-rep-f211a6db7e1ef0dd 2026-09-14T08:05:51.000Z weekly 0.7 https://www.pharmaradar360.com/article/quarterly-epidemiological-commentary-mandatory-mrsa-mssa-and-gram-negative-bacte-476c46b5e267decc 2026-09-14T08:02:51.000Z weekly 0.7 https://www.pharmaradar360.com/article/biontech-s-gotistobart-a-breakthrough-in-lung-cancer-treatment-3d84066f3e6cd42a 2026-09-14T08:01:27.000Z weekly 0.7 https://www.pharmaradar360.com/article/biontech-s-experimental-treatment-extended-survival-to-18-5-months-versus-10-0e0798bc527d2105 2026-09-14T08:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/vivian-l-borrero-rac-achieves-recognition-for-40-years-of-leadership-and-contrib-24dc3b41c574ff62 2026-09-14T07:57:36.000Z weekly 0.7 https://www.pharmaradar360.com/article/amivantamab-plus-chemotherapy-achieves-34-3-month-os-in-egfr-exon-20-insertion-l-0da3afd250e51aeb 2026-09-14T07:38:35.000Z weekly 0.7 https://www.pharmaradar360.com/article/tam-peli-extends-survival-to-13-3-months-in-relapsed-small-cell-lung-cancer-353338a24f94a9c6 2026-09-14T07:38:35.000Z weekly 0.7 https://www.pharmaradar360.com/article/mri-surveillance-alone-outperforms-mri-plus-radiation-in-sclc-trial-d1b659ade107b12a 2026-09-14T07:38:35.000Z weekly 0.7 https://www.pharmaradar360.com/article/emmaus-cedars-sinai-extend-pact-b072a5bba6875f3f 2026-09-14T07:38:22.000Z weekly 0.7 https://www.pharmaradar360.com/article/challenges-facing-chinese-biotech-deals-de6788d32d76210d 2026-09-14T07:37:54.000Z weekly 0.7 https://www.pharmaradar360.com/article/south-korean-pharmaceutical-company-plans-to-produce-medicines-in-kazakhstan-2b892242f692f4bd 2026-09-14T07:36:40.000Z weekly 0.7 https://www.pharmaradar360.com/article/kazakhstan-and-south-korea-agree-on-joint-pharmaceutical-production-7d2e8b6386b25bcf 2026-09-14T07:36:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/takeda-s-zasocitinib-wins-fda-priority-review-in-bid-to-redefine-oral-psoriasis-3f04a01589462c27 2026-09-14T07:34:03.000Z weekly 0.7 https://www.pharmaradar360.com/article/kazakhstan-and-south-korea-agree-on-joint-pharmaceutical-production-fed78451972c2e24 2026-09-14T07:30:59.000Z weekly 0.7 https://www.pharmaradar360.com/article/spotlight-on-innovative-pharmaceutical-companies-after-drug-pricing-reform-alteo-9d24cab8a2d849de 2026-09-14T07:20:27.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-approves-new-brain-cancer-imaging-agent-from-telix-dfce838ed16dbfa7 2026-09-14T07:07:29.000Z weekly 0.7 https://www.pharmaradar360.com/article/90-ad4b01e1c266920a 2026-09-14T07:04:02.000Z weekly 0.7 https://www.pharmaradar360.com/article/u-s-fda-accepts-new-drug-application-under-priority-review-for-takeda-s-zasociti-ef17f61352cd7eaa 2026-09-14T07:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/statement-on-pabs-instrument-at-the-eighth-meeting-of-the-intergovernmental-work-46d8f7c7cf3e1461 2026-09-14T06:58:22.000Z weekly 0.7 https://www.pharmaradar360.com/article/trump-s-drug-plan-could-prompt-companies-to-raise-prices-outside-the-us-86468b2325ec3197 2026-09-14T06:52:21.000Z weekly 0.7 https://www.pharmaradar360.com/article/kenya-explores-merck-partnership-in-biotechnology-and-local-pharmaceutical-manuf-4e4830bb94d8ddf5 2026-09-14T06:51:39.000Z weekly 0.7 https://www.pharmaradar360.com/article/nouveau-guide-destine-aux-promoteurs-pour-la-procedure-synchronisee-des-etudes-c-bf1ed68763a3326d 2026-09-14T06:48:58.000Z weekly 0.7 https://www.pharmaradar360.com/article/trastuzumab-botidotin-shows-11-1-month-pfs-vs-t-dm1-in-phase-3-trial-564267db7516eeaa 2026-09-14T06:43:35.000Z weekly 0.7 https://www.pharmaradar360.com/article/three-biotech-catalysts-to-watch-this-fall-rare-rapp-and-pcvx-nasdaq-rare-b87c087230a5836e 2026-09-14T06:37:37.000Z weekly 0.7 https://www.pharmaradar360.com/article/santen-pharmaceutical-new-drug-application-filing-accepted-for-review-in-china-f-5a0a1f604c868dd6 2026-09-14T06:37:11.000Z weekly 0.7 https://www.pharmaradar360.com/article/fourth-russian-attack-on-pharmaceutical-warehouse-this-month-facility-on-fire-in-fe9e711ab6f60d1d 2026-09-14T06:34:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/huons-teams-up-with-three-biotech-startups-for-joint-new-drug-development-expand-79cfd35f6eadf712 2026-09-14T06:33:25.000Z weekly 0.7 https://www.pharmaradar360.com/article/ad0e5b477a2967ca 2026-09-14T06:30:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/personnel-changes-7dcc223d059f37ef 2026-09-14T06:30:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/guide-destine-aux-promoteurs-pour-la-procedure-synchronisee-des-etudes-combinees-d566a9c40a897724 2026-09-14T06:22:55.000Z weekly 0.7 https://www.pharmaradar360.com/article/9lione-a-pharmaceutical-distribution-dx-company-raises-120-million-in-series-a-l-977358ce07543d12 2026-09-14T06:19:54.000Z weekly 0.7 https://www.pharmaradar360.com/article/rtw-biotech-opportunities-reports-august-nav-of-2-92-per-share-by-investing-com-f389326bb2eef80a 2026-09-14T06:10:25.000Z weekly 0.7 https://www.pharmaradar360.com/article/avacta-appoints-mats-blom-to-the-board-of-directors-as-chair-of-audit-committee-9cdbf75a711b7e6c 2026-09-14T06:01:42.000Z weekly 0.7 https://www.pharmaradar360.com/article/reg-rtw-biotech-opp-monthly-valuation-update-and-factsheet-2f129452d79a9f29 2026-09-14T06:01:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/yuhan-corporation-unveils-clinical-trial-design-for-oral-her2-cancer-drug-yh4294-e92301864336810f 2026-09-14T05:55:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-delays-review-of-exelixis-zanzalintinib-by-3-months-no-new-safety-issues-fou-406d52a642bf2331 2026-09-14T05:44:07.000Z weekly 0.7 https://www.pharmaradar360.com/article/daewon-pharmaceutical-hosts-vietnamese-delegation-at-smart-factory-c66774a452dccbe7 2026-09-14T05:37:43.000Z weekly 0.7 https://www.pharmaradar360.com/article/price-to-earnings-forward-of-cmg-pharmaceutical-co-ltd-krx-058820-402e367de1aa6bfc 2026-09-14T05:20:20.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-approves-viiv-s-tivicay-pd-for-newborn-hiv-patients-bc39eeceea971edb 2026-09-14T05:16:30.000Z weekly 0.7 https://www.pharmaradar360.com/article/allan-shaw-biotech-s-real-risk-isn-t-dilution-it-s-building-a-brand-of-generic-b90057b607ebcb91 2026-09-14T05:08:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/noxopharm-moves-lupus-skin-therapy-toward-next-human-trial-4c0656af8b7f5c97 2026-09-14T05:04:02.000Z weekly 0.7 https://www.pharmaradar360.com/article/4-best-gene-editing-stocks-for-2026-and-how-to-invest-2370cdd322149d26 2026-09-14T04:31:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/rebuilding-food-safety-regulation-in-the-united-states-c37766891763882d 2026-09-14T04:23:46.000Z weekly 0.7 https://www.pharmaradar360.com/article/ivonescimab-monotherapy-demonstrates-a-statistically-significant-clinically-mean-de95279f4726a52b 2026-09-14T03:57:18.000Z weekly 0.7 https://www.pharmaradar360.com/article/zipalertinib-plus-chemotherapy-demonstrates-6-month-median-progression-free-surv-9d2c4846e90ee934 2026-09-14T03:57:18.000Z weekly 0.7 https://www.pharmaradar360.com/article/astrazeneca-s-drug-delayed-lung-cancer-progression-by-6-months-in-a-trial-85662fec9375d10a 2026-09-14T03:56:15.000Z weekly 0.7 https://www.pharmaradar360.com/article/china-warns-us-over-alleged-espionage-targeting-ai-chip-biotech-companies-bf9f9adcacb5b3da 2026-09-14T03:36:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/79-were-alive-eight-years-later-on-astrazeneca-s-lung-cancer-drug-versus-64-on-p-98fd92d7250b9744 2026-09-14T02:18:14.000Z weekly 0.7 https://www.pharmaradar360.com/article/phase-3-destiny-lung04-trial-shows-first-line-trastuzumab-deruxtecan-significant-547549369a0f3eab 2026-09-14T02:13:20.000Z weekly 0.7 https://www.pharmaradar360.com/article/cullinan-taiho-showcase-6-month-survival-benefit-in-phase-3-trial-for-advanced-l-ac746721ed14d229 2026-09-14T01:44:33.000Z weekly 0.7 https://www.pharmaradar360.com/article/ai-driven-pharmaceutical-r-d-infrastructure-competition-key-trends-strategies-in-a02a6e13d45ee46d 2026-09-14T01:11:43.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-eastward-shift-in-the-biotech-world-why-india-and-china-could-lead-the-next-c7351acce8a9a57e 2026-09-14T01:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/zipalertinib-plus-chemotherapy-demonstrates-6-month-median-progression-free-surv-d8ea6923c50c50be 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/astrazeneca-filed-form-6-k-8f0a4cbe341f351b 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/biontech-filed-form-6-k-47a909258d7896e0 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/gsk-filed-form-6-k-e03dfe4679ebf435 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/santen-new-drug-application-filing-accepted-for-review-in-china-for-stn1012700-a-f5d677282047d1cf 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/natco-records-e2-82-b9816-9-crore-consolidated-revenue-and-e2-82-b9269-0-crore-o-43af7f508aad5808 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/natco-records-e2-82-b9794-4-crore-consolidated-revenue-and-e2-82-b9206-5-crore-o-0a2f52c48bbe338f 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/natco-records-e2-82-b9705-4-crore-consolidated-revenue-and-e2-82-b9151-3-crore-o-22092c86d7df9466 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-olaparib-tablets-from-the-united-states-fo-2d158a641081c0cd 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/natco-receives-approval-from-central-drug-standard-control-organisation-cdsco-fo-d076b55218c8a2fb 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/natco-pharma-limited-gets-approval-from-its-board-of-directors-for-increasing-it-2e7d222acc44a9c2 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/natco-pharma-limited-completes-acquisition-of-additional-13-25-stake-in-adcock-i-dbbe71b996495e15 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/natco-pharma-limited-api-unit-in-chennai-receives-establishment-inspection-repor-a565d16132d7098a 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/natco-pharma-limited-announces-conclusion-of-us-fda-inspection-at-visakhapatnam-41789f04c6bc98f9 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/natco-pharma-launches-semaglutide-generic-injection-multi-dose-vials-in-india-at-e8036bd141f5d31d 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/natco-announces-launch-of-pomalidomide-capsules-generic-of-pomalyst-in-the-u-s-m-50744185ac6a0574 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/natco-and-lupin-receive-approval-from-u-s-fda-for-eribulin-mesylate-injection-368730ee7afce07f 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/investment-of-us-14-million-in-egenesis-inc-by-natco-pharma-canada-inc-and-natco-3eebdf6c19a690f3 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/home-page-4ff70bffc7142a1d 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/importer-of-controlled-substances-application-irvine-labs-inc-1350cffdd1f6ab38 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/bulk-manufacturer-of-controlled-substances-application-cambrex-high-point-inc-008e3b2bc6e1d789 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/agency-forms-undergoing-paperwork-reduction-act-review-dce179460387c8ae 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/announcing-the-intent-to-award-a-single-source-supplement-for-expanding-outreach-f9898d8cf2a86252 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/solicitation-for-nominations-to-serve-on-the-advisory-council-to-support-grandpa-6ebc6e265a932df5 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/solicitation-for-nominations-to-serve-on-the-family-caregiving-advisory-council-31910611e58db2c4 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/agency-information-collection-activities-submission-for-office-of-management-and-8f8b60381133a48a 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/office-of-the-national-coordinator-for-health-information-technology-health-info-b544a4acb9b8b8f6 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/agency-information-collection-activities-proposed-collection-comment-request-b02f31e37dc3ec91 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/proposed-collection-60-day-comment-request-nih-electronic-application-system-for-1920dece3f62af8f 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/draft-nih-biosafety-policy-for-research-involving-biohazards-29b2690afa1577d6 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/cleveland-clinic-begins-offering-appointment-only-flu-vaccinations-5c438e2467aed99f 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/smart-pharmaceutical-packaging-market-forecast-report-featuring-segment-analysis-55a8d6ef43850c1d 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/implications-of-potential-us-fda-approval-of-psychedelics-or-psychedelic-adjacen-8b3f3520f48b0627 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/efficacy-and-safety-of-celecoxib-combined-with-jintiange-capsules-for-the-treatm-e71b3692cb8b1294 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/lipoprotein-a-in-japan-an-expert-consensus-statement-9e5280d6ea38688c 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/encarcelando-eslabones-descartables-microtrafico-en-mujeres-bolivianas-y-su-vinc-78099e7bb631f301 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/endoscopic-retrograde-cholangiopancreatography-versus-endoscopic-ultrasound-guid-06fe4129655d1ee6 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/comparison-of-outcome-of-sac-ligation-versus-no-sac-ligation-in-pediatric-patien-532a18f6cf6f4daa 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/comparative-trial-of-periumbilical-incision-versus-intraumbilical-incision-in-em-3b7d7e84584d0075 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/penicillin-a-journey-from-a-magic-bullet-to-a-resistant-drug-9f783258c6f90946 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/inside-the-community-alongside-clinical-practice-community-music-therapy-as-soci-e648dcea05dfc2dc 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/tuberculosis-resistente-a-farmacos-y-factores-asociados-en-santa-fe-2021-2024-c10ac6bde98c4961 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/in-silico-adme-toxicity-profiling-of-3-4-dithia-1-azabicyclo-3-2-0-heptan-7-one-caf23f7a863538aa 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/genicular-artery-embolization-in-primary-and-secondary-knee-osteoarthritis-clini-9bb5724954bb9262 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-outcomes-of-tep-and-lichtenstein-repair-in-bilateral-inguinal-hernia-su-75f20d92150782da 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-significance-of-incidental-colorectal-fdg-avid-lesions-on-oncologic-18f-ed6e93d4e1e114be 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-effect-of-soft-tissue-mobilization-and-kinesio-taping-on-sportive-performanc-99d998bcb0793088 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/unveiling-ai-augmented-periodontal-decision-making-a-comparative-clinical-evalua-afd3857e16b239eb 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/utilization-of-long-acting-injectable-antipsychotics-and-clozapine-in-coordinate-b1a839103df3000d 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-translational-nephrology-in-global-primary-care-bridging-innovation-pre-7f9c25f39ef7100a 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/diagnostic-performance-of-fine-needle-aspiration-i-vs-i-fine-needle-biopsy-in-so-dbf723366d924d81 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/rural-urban-differences-in-breast-cancer-epidemiology-nutritional-status-and-cli-bbc480129a89ee6a 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/quasi-experimental-trial-examining-the-effectiveness-of-driver-training-modules-b9eb6d77db7b1dab 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-translation-of-fisetin-for-age-related-diseases-current-evidence-and-fu-3668d87d5ee7a0ca 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/asthma-and-sinonasal-diseases-shared-clinical-comorbidities-inflammatory-pathway-afac4b7bf1e62340 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/preoperative-frailty-inflammation-phenotypes-and-early-functional-and-patient-re-7f649c25063dbf2a 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/prenatal-and-postnatal-identification-of-phelan-mcdermid-syndrome-in-a-tertiary-1992aa669c4b0d5e 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-impact-of-differential-posterior-tibial-slope-on-clinical-outcomes-following-42a7ccaaa95fd46c 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/paired-urinary-cytology-and-targeted-fgfr3-s249c-r248c-mutation-detection-in-uri-4f195e94a047b77e 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/serum-granzyme-b-in-parkinson-s-disease-a-case-control-study-of-diagnostic-assoc-915548369384ad65 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-outcomes-of-ankaferd-hemostat-mouthwash-for-high-grade-oral-mucositis-d-dd6bbd11a2889475 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/responsible-clinical-ai-in-dentistry-trust-professional-autonomy-and-perceptions-bf5bf089fe84f1c4 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-global-burden-of-eustachian-tube-dysfunction-in-older-patients-pathophysiolo-458aaa33a1cfbbdc 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/therapeutic-advances-in-spinal-muscular-atrophy-a-review-of-clinical-safety-and-d99e25370b464471 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/assessment-of-minimum-discard-volume-for-central-venous-catheter-sampling-valida-face44472c6caf57 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/artificial-intelligence-in-colorectal-cancer-multidisciplinary-decision-making-c-5b2c364273f7c68c 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/piwil4-from-biological-characteristics-to-disease-pathogenesis-and-clinical-appl-fe625d656dadd63f 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/secretory-carrier-membrane-protein-3-modulates-nuclear-erk1-2-signaling-and-drug-f0a176772406d686 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/medicinal-mushrooms-and-type-2-diabetes-mechanistic-insights-translational-evide-c67fcbde1cdfbd95 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-clinical-effects-of-probiotic-supplementations-on-metabolic-syndrome-a-syste-3ee1432f47c34b56 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/controlled-low-central-venous-pressure-after-cardiopulmonary-bypass-reduces-acut-377e84517695fe80 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/immune-microbe-interactions-in-pediatric-ulcerative-colitis-clinical-features-pa-a9a0449f50bfee25 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/immune-checkpoint-inhibitor-associated-arrhythmias-clinical-challenges-artificia-ae5d84fef5706750 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/porous-silicon-nanoparticles-in-drug-delivery-regenerative-medicine-and-biosensi-1227a29e48efd94e 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/closed-loop-non-invasive-ventilation-in-critical-care-current-evidence-and-clini-2f6f8236ab093dda 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/unraveling-the-mystery-of-status-epilepticus-a-retrospective-study-at-a-tertiary-a9048ab8cd680ff1 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/evaluation-of-biofertigation-for-enhancing-growth-and-yield-of-blackgram-vigna-m-ac7b85d563f235a6 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/comparative-phytochemical-screening-and-in-vitro-anthelmintic-evaluation-of-etha-ce97e601cabab040 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/modified-tibial-plateau-leveling-osteotomy-using-a-precontoured-plate-achieves-s-73e5b5184a8265e7 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-computational-study-of-some-cancer-causing-s100-proteins-interacting-with-a-li-03ed20d4c40a4d43 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/pharmaceutical-care-for-patients-with-leprosy-impact-on-treatment-adherence-and-008e2fd16c1d0c1c 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/development-and-external-validation-of-a-machine-learning-based-clinical-predict-4d88db5e80c48cba 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/associations-of-pretreatment-neutrophil-to-lymphocyte-ratio-and-thyroid-related-dbbd59bacc22f2b8 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-effect-of-reminiscence-therapy-on-the-resilience-and-satisfaction-with-care-d442db71ae84ac7c 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/beta-lactam-dose-optimization-using-therapeutic-drug-monitoring-in-pediatric-pat-e3ca0a48c61a6b6b 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/preparation-of-transdermal-patch-as-a-drug-delivery-system-for-treatment-of-urin-b682b2e2a273a1b5 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/interference-by-saline-based-reconstitution-of-lyophilized-quality-control-plasm-4b8636f570f38727 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/efficacy-and-safety-of-celecoxib-combined-with-jintiange-capsules-for-the-treatm-f8b897f6293fe297 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-significance-of-resting-and-dobutamine-stress-myocardial-work-in-cirrho-2c6fc0ec97666692 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/improving-therapist-adoption-of-evidence-based-practices-with-the-loci-strategy-49a6ac97edcbf0df 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/analysis-of-the-role-experiences-of-clinical-nurse-educators-in-the-process-of-i-5723d793e7d5ea7c 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-survey-on-the-current-clinical-use-and-perceptions-of-warm-needle-acupuncture-ecb43b6a39884080 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-efficacy-and-safety-of-curcumin-for-the-prevention-and-treatment-of-rad-3adc6b63e3e0b97b 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/non-invasive-biofeedback-assisted-vs-conventional-pelvic-floor-muscle-training-c-c024152c1924ea13 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/post-implementation-changes-in-the-procurement-volume-and-patterns-of-oral-hypog-12f2a4df784c8026 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-characteristics-of-infective-endocarditis-in-children-a-single-center-o-155b307787d443f8 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/potential-clinical-value-of-mir-122-expression-and-genetic-locus-variants-in-ped-2c58e79476f42db4 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-prognostic-model-integrating-systemic-inflammation-and-clinical-features-for-o-4ba9b87bf15bafe3 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/preventability-of-adverse-drug-reactions-to-anticancer-drugs-insights-from-the-d-6e0304153ab4cab5 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/association-of-intraoperative-systolic-blood-pressure-variability-and-clinical-o-ba5dfdd788dcf654 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/advances-in-drug-delivery-systems-for-osteoarthritis-therapy-exosomes-microparti-e0b306b586959ea6 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/paired-oral-clinical-specimens-reveal-the-underlying-ecology-supporting-the-emer-452251b0fbaa9af4 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/library-strategies-differentially-shape-microbial-functional-and-host-signals-in-ed7d88ee8c97421b 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/palmar-plantar-ligament-injuries-in-five-horses-clinical-findings-comparative-di-5236f722da22c599 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/pseudoangiomatous-stromal-hyperplasia-of-the-breast-clinical-radiologic-and-hist-ab64f7b05784a45f 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/assessment-of-pharmacy-professionals-workplace-satisfaction-in-a-conflict-affect-b9bccd32f45054ac 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-future-of-pharmaceuticals-strategic-foresight-in-an-era-of-uncertainty-aa902f719a466343 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-progress-in-gene-therapy-for-rpgr-associated-x-linked-retinitis-pigment-54539ea3fc0cc69f 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/hydrogen-bonded-poly-vinyl-alcohol-tannic-acid-quercetin-hydrogels-for-localized-ac652fd7b3c4269d 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/i-in-vitro-i-assessments-for-pharmacokinetic-drug-drug-interaction-potential-of-cf08e40435812d90 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/hydrogen-rich-water-ingestion-alleviates-downhill-running-induced-muscle-sorenes-d0207f0a4e64aea6 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nat10-as-a-context-dependent-epitranscriptomic-hub-governing-cancer-drug-resista-22f80dfb63466a0b 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/impact-of-vascular-and-cardiac-parameters-on-quality-of-life-in-patients-undergo-a52b60a8304f8b42 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/old-drug-with-new-application-spironolactone-suppresses-panx-1-mediated-ca2-infl-01c4d8120aeb176c 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/craniofacial-morphology-and-dental-age-assessment-in-pediatric-craniosynostosis-4c9a55058c7e2458 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/environmental-burdens-of-long-term-cadaver-pool-storage-solutions-a-screening-cr-4d8320b83900e71e 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/practical-computational-exploration-of-chemical-reaction-space-assessing-the-che-e45d4b674d9e7dbf 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/neonatal-ventilation-training-using-a-low-cost-high-fidelity-simulator-in-a-low-352ce6c5484f86fe 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07819110-radicle-healthtm-vip-a-study-assessing-the-impact-of-health-and-well-306e35e216d7a229 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07818590-the-effect-of-nanoparticle-coating-of-orthodontic-brackets-on-the-ra-45cd5b663cc584f2 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07818395-spatial-multi-omics-of-perineural-invasion-microenvironment-and-prog-9eae5da708518537 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07818174-graded-motor-imagery-effects-on-body-perception-disturbance-in-compl-6fa37c136a3eadb5 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07817186-clinical-trial-of-a-mek-inhibitor-for-rasopathy-associated-severe-in-cfc658dba67c417c 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07817004-qlm2010-comparative-pharmacokinetic-study-with-2-minute-intravenous-90a7bd456c2fdff5 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07816731-effect-of-face-to-face-and-virtual-reality-based-salutogenesis-nursi-b72760fa4d356199 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07816666-torvutatug-samrotecan-with-or-without-bevacizumab-as-maintenance-tre-ef10e449d172cc7f 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07815678-first-in-human-study-of-the-safety-tolerability-pharmacokinetics-and-7bfba9cc2885eb22 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07810478-criteria-based-rehabilitation-after-tibial-fracture-fixation-a-rando-a829f93786110c1b 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07739459-study-of-zanubrutinib-in-older-patients-with-previously-untreated-ch-8e97594244b216f5 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07686380-il-15-superagonist-with-or-without-vaccine-in-biochemically-recurren-cfd5e39e4ab2fd00 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07673913-relationship-of-peripheral-inflammatory-and-neuroprotective-biomarke-2ca4185331048bcb 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07554339-a-clinical-trial-of-calderasib-mk-1084-and-durvalumab-in-people-with-8682652bb67ca21f 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07516184-explore-the-diagnostic-value-of-bronchodilation-test-with-portable-o-5c13347c1faf4c64 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07513389-omission-of-postoperative-radiation-in-hpv-associated-oropharyngeal-54433fa6534bad2b 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07465757-a-study-of-alisertib-and-paclitaxel-in-patients-with-small-cell-lung-dde461375ff0295b 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07451899-tb-type-and-spirometry-result-vs-functional-capacity-based-on-6mwt-i-21d29ab24081d675 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07218146-a-study-of-zl-1310-versus-investigator-s-choice-of-therapy-in-partic-767ee1cfeea38d53 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07111065-fast-for-dm-fatty-acid-supplementation-trial-fast-for-dermatomyositi-ed2b3f59cab40468 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07098351-efficacy-and-safety-of-nalfurafine-hydrochloride-odt-for-moderate-to-095639059132fe18 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06991738-177lu-dota-eb-tate-in-adult-patients-with-metastatic-radioactive-iod-8bb88397e09523fd 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06899308-health-surveillance-at-constructor-university-bremen-cub-5de96b94d7255aa9 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06860698-the-impact-of-chronic-e-cigarette-usage-on-microvascular-health-fd1ed5abb1124fed 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06820463-a-study-to-evaluate-the-adverse-events-and-efficacy-of-intravenous-i-8e023f916ad246b4 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06797661-insights-into-the-pathophysiology-of-neurovascular-uncoupling-in-pat-88c52fa05421580c 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06794125-an-evaluation-of-dose-escalation-for-intrathoracic-tumours-03fc06b394cbb28a 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06789198-peptide-vaccine-for-fibrolamellar-hepatocellular-carcinoma-patients-73706391bfa20375 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06595940-genetic-analysis-of-uncommon-disease-presentations-in-non-us-populat-9a7defcdd77feca2 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06590051-amg-335-expanded-access-program-for-igg4-related-disease-c8325929e8dbbc09 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06549153-act-together-acting-on-cancer-testing-together-a08de136fdf3c7c8 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06282575-efficacy-and-safety-of-zanidatamab-with-standard-of-care-therapy-aga-f51095141a5f7f25 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06263283-impact-of-an-educational-physiotherapy-yoga-intervention-on-perceive-9a1f907fc02817ea 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06065748-a-study-to-evaluate-efficacy-and-safety-of-giredestrant-compared-wit-0ef2bd2d0a1567bf 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct05827081-phase-iiib-study-of-ribociclib-et-in-early-breast-cancer-af4028810169a04c 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct05642195-evaluation-of-a-cancer-lysate-vaccine-and-montanide-registered-trade-6c3881e00781f72d 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct05482516-evaluating-novel-therapies-in-ctdna-positive-gi-cancers-6ccbf36dce5d5e63 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct05172245-testing-the-addition-of-ipatasertib-to-usual-chemotherapy-and-radiat-f6b6c429408def1b 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct05041387-data-collection-of-standard-care-of-patients-in-the-emg-section-ac1d0af4063522b8 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct04751409-evaluating-the-impact-of-limited-compared-with-intense-post-operativ-3914dd6bd3bf878c 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct04708067-hypofractionated-radiation-therapy-and-bintrafusp-alfa-for-the-treat-cbd312bb31198efe 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct04543617-a-study-of-atezolizumab-with-or-without-tiragolumab-in-participants-78dab5b9bab22eb7 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct04449549-rapid-analysis-and-response-evaluation-of-combination-anti-neoplasti-ff3252eaf85eba3c 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct04221750-diet-and-exercise-plus-metformin-to-treat-frailty-in-obese-seniors-5d3925a3863eaf7b 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct04115631-a-comparison-of-three-chemotherapy-regimens-for-the-treatment-of-pat-12d28c00c5a80ada 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct04021329-efficacy-of-eye-movement-desensitization-reprocessing-versus-cogniti-3e36390b02b80510 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct03683433-enasidenib-and-azacitidine-in-treating-patients-with-recurrent-or-re-cbfde361bf4fd7fc 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct03533582-cisplatin-and-combination-chemotherapy-in-treating-children-and-youn-b835c20426c4e184 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct03214562-venetoclax-with-combination-chemotherapy-in-treating-patients-with-n-1046bc1f29df907e 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct03137511-optimizing-access-to-care-through-new-technologies-a-randomized-stud-4da9fa163d38b237 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct02698579-long-term-follow-up-of-participants-with-cerebral-adrenoleukodystrop-d760eb80889e1868 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct01660984-natural-history-study-of-children-and-adults-with-medullary-thyroid-5dc6ce49fdf8cca4 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct01630278-early-ibuprofen-treatment-of-patent-ductus-arteriosus-pda-in-prematu-9425d0c4c406003d 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct01386034-effects-of-oral-citrulline-on-protein-metabolism-in-patients-with-in-2d6bd6a6fb3bf396 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct01061255-stress-and-clinical-reasoning-in-medical-students-c8bea47dc082710b 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct00841724-study-of-a-reduced-toxicity-submyeloablative-conditioning-regimen-pr-a06f1679c838c0a1 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct00791635-longitudinal-evaluation-of-women-undergoing-pelvic-surgery-for-the-t-44d99c489e3f4c7a 2026-09-14T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/sk-biopharmaceuticals-second-drug-hits-fda-safety-hurdle-78904628f6a4b1e0 2026-09-13T23:59:28.000Z weekly 0.7 https://www.pharmaradar360.com/article/report-ge-healthcare-to-buy-sofie-biosciences-for-1-billion-as-part-of-pharmaceu-76ac7840b032d4ac 2026-09-13T23:44:12.000Z weekly 0.7 https://www.pharmaradar360.com/article/gsk-prepares-frontline-fda-bid-for-jideytro-its-first-lung-cancer-drug-0f6add197193563c 2026-09-13T23:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/pharmaceutical-dispersants-market-forecast-to-2035-biologics-and-cell-therapy-dr-20b76c50b6aa2cee 2026-09-13T22:56:18.000Z weekly 0.7 https://www.pharmaradar360.com/article/new-us-medicare-pricing-policies-could-reshape-global-pharmaceutical-markets-796dc218c7715e5a 2026-09-13T22:30:01.000Z weekly 0.7 https://www.pharmaradar360.com/article/amgen-stock-faces-pressure-after-rival-s-clinical-trial-miss-2ebdc81c4c996a43 2026-09-13T22:15:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/gas-preheating-modules-market-forecast-to-2035-growth-driven-by-semiconductor-an-b55c48aa66aef3e6 2026-09-13T21:26:17.000Z weekly 0.7 https://www.pharmaradar360.com/article/south-korea-advances-medical-cannabis-as-neocannbio-builds-gmp-capacity-chosunbi-24a6a75a7ed952d4 2026-09-13T21:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/health-journey-from-ebola-to-innovative-treatments-8194ac8c0bba5c74 2026-09-13T20:58:09.000Z weekly 0.7 https://www.pharmaradar360.com/article/emyria-to-speak-at-us-fda-hearing-3c0cbf4041772dcb 2026-09-13T20:55:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/servier-partnering-day-connecting-pharma-biotech-and-academia-for-new-opportunit-e9b0088d23d43ad2 2026-09-13T20:54:18.000Z weekly 0.7 https://www.pharmaradar360.com/article/uncy-stock-on-track-for-worst-day-in-about-a-year-ahead-of-fda-decision-on-lead-781ead4101837786 2026-09-13T20:37:31.000Z weekly 0.7 https://www.pharmaradar360.com/article/from-kerala-pappadam-rules-to-old-monk-scrutiny-when-routine-food-and-drug-enfor-1a02121b9e57e7f2 2026-09-13T20:19:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/sls-stock-snaps-2-day-slide-sellas-sls009-aml-trial-spotlights-big-pharma-drug-c-f36c0d0b6d235967 2026-09-13T20:03:33.000Z weekly 0.7 https://www.pharmaradar360.com/article/gsk-presents-positive-registrational-data-to-potentially-expand-jideytro-zidesam-61324be0e8c113f6 2026-09-13T19:30:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/etfs-investing-in-zhejiang-chengyi-pharmaceutical-co-ltd-class-a-stocks-a4002021b818d1df 2026-09-13T17:38:31.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-breakthrough-cancer-vaccine-fueled-a-biotech-rally-can-it-last-16c0e73db8d97a9a 2026-09-13T17:34:07.000Z weekly 0.7 https://www.pharmaradar360.com/article/centric-compounding-issues-nationwide-recall-of-glutathione-myer-s-cocktail-and-b5a72d52260ba24e 2026-09-13T16:45:04.000Z weekly 0.7 https://www.pharmaradar360.com/article/top-biotech-stocks-to-watch-today-september-13th-ac86db9ba49d8ae3 2026-09-13T16:04:30.000Z weekly 0.7 https://www.pharmaradar360.com/article/peptides-approved-so-far-have-limited-human-research-748b4e7ba137702b 2026-09-13T15:52:42.000Z weekly 0.7 https://www.pharmaradar360.com/article/makinde-others-to-grace-psn-oyo-2026-world-pharmacists-day-f74cb2bf371b0c73 2026-09-13T15:32:38.000Z weekly 0.7 https://www.pharmaradar360.com/article/dbvt-slides-as-dbv-technologies-leads-european-biotech-declines-bfb64ba5124bdf18 2026-09-13T15:05:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/how-to-trade-this-2-billion-biotech-name-moving-quickly-toward-profit-e72df0c44deb6bd8 2026-09-13T15:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/3-small-cap-biotechs-with-binary-catalysts-on-the-calendar-451f0e34f912ed8e 2026-09-13T14:52:31.000Z weekly 0.7 https://www.pharmaradar360.com/article/3-small-cap-biotechs-with-binary-catalysts-on-the-calendar-3c11057fc1f82d23 2026-09-13T14:50:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/pharma-drugs-from-other-states-emerge-as-new-challenge-for-punjab-police-964229af63a04d03 2026-09-13T13:58:50.000Z weekly 0.7 https://www.pharmaradar360.com/article/yesterday-when-i-was-young-how-grief-and-music-motivate-this-hong-kong-biotech-s-6bbb76fd500ed8c5 2026-09-13T12:33:35.000Z weekly 0.7 https://www.pharmaradar360.com/article/drinking-water-in-pet-bottles-found-safe-fda-402bb54191a107af 2026-09-13T12:33:08.000Z weekly 0.7 https://www.pharmaradar360.com/article/novartis-stock-stabilizes-after-trial-setbacks-as-investor-pushes-for-board-shak-91c49459cb9bde0d 2026-09-13T12:19:52.000Z weekly 0.7 https://www.pharmaradar360.com/article/roivant-sciences-diverse-exposure-to-biotech-niches-through-vants-nasdaq-roiv-f755b46573c262a0 2026-09-13T11:30:08.000Z weekly 0.7 https://www.pharmaradar360.com/article/punjab-sees-shift-in-drug-trade-heroin-availability-falls-pharmaceutical-narcoti-3c356b6a4ec030fc 2026-09-13T11:19:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/heroin-supply-falls-in-punjab-but-pharma-drugs-from-other-states-emerge-as-new-c-553dd4232e825186 2026-09-13T11:13:13.000Z weekly 0.7 https://www.pharmaradar360.com/article/etfs-investing-in-hebei-changshan-biochemical-pharmaceutical-co-ltd-class-a-stoc-12d05f5761881b7d 2026-09-13T11:12:17.000Z weekly 0.7 https://www.pharmaradar360.com/article/india-s-patent-office-issues-draft-guidelines-for-pharma-biotech-patents-f5ea25ff845c0d58 2026-09-13T10:20:22.000Z weekly 0.7 https://www.pharmaradar360.com/article/kardigan-funded-precision-cardiology-offers-more-than-pipeline-diversification-903862474345a45e 2026-09-13T10:10:26.000Z weekly 0.7 https://www.pharmaradar360.com/article/aan-ahs-issue-updated-guideline-on-migraine-prevention-atogepant-meets-end-point-fba9ebb04f21030b 2026-09-13T10:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/scientist-challenges-pharmaceutical-ceo-7d668b086603b6da 2026-09-13T09:34:19.000Z weekly 0.7 https://www.pharmaradar360.com/article/mirum-s-azure-3-trial-a-new-switch-strategy-in-chronic-hepatitis-d-7e2f82ccd93e8fa1 2026-09-13T09:17:51.000Z weekly 0.7 https://www.pharmaradar360.com/article/pharmacists-and-civic-groups-in-south-korea-rally-to-block-telemedicine-drug-del-b3f335563b1d4740 2026-09-13T08:37:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/kush-choksi-promoted-to-assistant-vice-president-business-development-at-strides-67d859a68cdf70fc 2026-09-13T08:25:55.000Z weekly 0.7 https://www.pharmaradar360.com/article/russians-attack-ukraine-s-second-largest-pharmaceutical-warehouse-twice-e64594d4abfd7904 2026-09-13T08:13:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/merali-family-acquires-stake-in-sh330-million-mombasa-glass-plant-534ff22c2cb25d15 2026-09-13T08:06:33.000Z weekly 0.7 https://www.pharmaradar360.com/article/california-state-teachers-retirement-system-grows-holdings-in-teva-pharmaceutica-401670e366181271 2026-09-13T08:06:09.000Z weekly 0.7 https://www.pharmaradar360.com/article/indian-patent-office-releases-draft-pharma-and-biotech-patent-rules-745c2dc8449c8b47 2026-09-13T08:04:40.000Z weekly 0.7 https://www.pharmaradar360.com/article/ris-rez-reduced-risk-of-death-by-54-versus-topotecan-in-patients-with-relapsed-s-bc1325534320d150 2026-09-13T08:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/mcaz-remedica-medicine-recall-zimbabwe-for-nifedipine-levodopa-4a21d23560bf1cee 2026-09-13T07:29:52.000Z weekly 0.7 https://www.pharmaradar360.com/article/mitapivat-just-rewrote-the-treatment-floor-for-transfusion-dependent-thalassaemi-0e1aeb228fea5f5f 2026-09-13T07:28:29.000Z weekly 0.7 https://www.pharmaradar360.com/article/indian-patent-office-proposes-new-guidelines-for-pharma-patent-examination-5171aedfc3e70ab9 2026-09-13T07:21:44.000Z weekly 0.7 https://www.pharmaradar360.com/article/tam-peli-meets-primary-endpoint-for-relapsed-small-cell-lung-cancer-in-phase-iii-ac7af87a08f589ad 2026-09-13T06:38:27.000Z weekly 0.7 https://www.pharmaradar360.com/article/iza-bren-2-5-mg-kg-dose-advances-to-phase-3-in-egfr-mutated-nsclc-70789e99d842e835 2026-09-13T06:38:27.000Z weekly 0.7 https://www.pharmaradar360.com/article/j-j-exits-laa-closure-market-sells-laminar-program-to-jaguar-laa-77731cf65f918dd3 2026-09-13T06:38:27.000Z weekly 0.7 https://www.pharmaradar360.com/article/aurobindo-s-curateq-biologics-reports-positive-phase-3-results-for-omalizumab-bi-65c6bb10b421292e 2026-09-13T06:07:52.000Z weekly 0.7 https://www.pharmaradar360.com/article/ntla-stock-surges-35-overnight-retail-mood-peaks-ahead-of-first-ever-phase-3-rea-d5beb93535a18e5e 2026-09-13T05:49:54.000Z weekly 0.7 https://www.pharmaradar360.com/article/supreme-court-asked-to-restore-access-to-mail-order-abortion-pill-mifepristone-20d9cb41edbc928e 2026-09-13T04:08:40.000Z weekly 0.7 https://www.pharmaradar360.com/article/antibody-drug-combination-falls-short-in-first-line-pd-l1-high-metastatic-lung-c-355a95d6d905ce35 2026-09-13T04:02:58.000Z weekly 0.7 https://www.pharmaradar360.com/article/holiferm-and-organica-uk-combine-to-build-integrated-biotech-and-sustainable-pro-326ddd6adcb0a06e 2026-09-13T02:17:04.000Z weekly 0.7 https://www.pharmaradar360.com/article/akeso-summit-s-ivonescimab-tops-keytruda-in-lung-cancer-survival-with-strong-dat-63d1edeae3bf3d46 2026-09-13T01:45:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/merck-gilead-s-failed-trodelvy-lung-cancer-trial-shows-better-china-results-76c37bd818cc89c6 2026-09-13T01:44:19.000Z weekly 0.7 https://www.pharmaradar360.com/article/bhushan-malpure-elevated-to-head-of-marketing-at-cipla-9e97a17d55f1f388 2026-09-13T01:26:14.000Z weekly 0.7 https://www.pharmaradar360.com/article/polyester-thermal-ribbon-material-market-forecast-to-2035-driven-by-coding-and-m-423a025c3eff05f6 2026-09-13T00:41:22.000Z weekly 0.7 https://www.pharmaradar360.com/article/sls-stock-hits-over-3-year-high-as-aml-drug-trial-nears-final-readout-wall-stree-d690b1c596b74875 2026-09-13T00:37:31.000Z weekly 0.7 https://www.pharmaradar360.com/article/roche-s-cancer-drug-cut-death-risk-54-in-a-phase-iii-trial-aa806bf235967344 2026-09-13T00:13:14.000Z weekly 0.7 https://www.pharmaradar360.com/article/roche-s-collaborator-medilink-announces-phase-iii-data-for-tam-peli-showing-sign-59cd66eaa83f33ab 2026-09-13T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/integrated-analysis-of-her2-expression-and-erbb2-alterations-in-bladder-cancer-4ea80dc605ea0fc0 2026-09-13T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/linezolid-in-the-era-of-bedaquiline-pretomanid-linezolid-based-regimens-an-indis-8e924ce3b153dea5 2026-09-13T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/safety-and-tolerability-of-linezolid-to-treat-tuberculosis-a-systematic-review-a-fb2e66d13330fbbb 2026-09-13T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/pharmacokinetic-and-safety-interactions-between-aildenafil-and-clarithromycin-ci-9c218951a83f2a36 2026-09-13T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/transfascial-paraspinal-versus-conventional-open-posterior-pedicle-screw-fixatio-702e3f0c54fd95bc 2026-09-13T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/when-fever-hides-fire-a-systematic-review-of-clinical-and-digital-approaches-to-3b1675982556c63d 2026-09-13T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/integrated-clinical-biological-and-echocardiographic-factors-independently-assoc-d9399d45b2a33f73 2026-09-13T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/an-interpretable-machine-learning-technique-for-chronic-kidney-disease-diagnosis-a36eb0bcde8fec07 2026-09-13T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/hemodynamic-assessment-of-different-septic-shock-resuscitation-strategies-a-comp-2e608c74e044dc35 2026-09-13T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/lt-b-gt-daily-versus-thrice-weekly-antituberculosis-therapy-for-drug-susceptible-0c5ecbecd8d647ea 2026-09-13T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/phenotypic-biofilm-formation-and-detection-of-biofilm-associated-genes-in-multid-36922277a1ca5ce2 2026-09-13T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/long-term-dupilumab-therapy-in-atopic-dermatitis-and-prurigo-nodularis-clinical-3093d0df68a96ae7 2026-09-13T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/directions-for-improving-drug-provision-for-outpatients-with-diabetes-mellitus-c70325f08c56201e 2026-09-13T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/assessment-of-the-informativeness-of-the-snot-22-questionnaire-in-patients-with-4e9dcdbe265cd94a 2026-09-13T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/altered-pharmacokinetics-and-drug-dosing-in-obese-patients-a-traditional-review-e229aee037800092 2026-09-13T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/ethical-ai-for-crisis-response-a-dynamic-policy-orchestrator-for-prescriptive-re-430bd70d0146756a 2026-09-13T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-spectrum-and-electroencephalographic-correlation-in-subacute-sclerosing-22af5f8f19051f51 2026-09-13T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/metabolic-consequences-of-vitamin-b6-deficiency-and-their-impact-on-lipid-metabo-27d51c561cbb492d 2026-09-13T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/subclinical-thyroid-dysfunction-when-to-treat-and-when-to-observe-a-comprehensiv-6559b87113af5617 2026-09-13T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/evaluating-public-acceptance-of-the-official-medicine-label-and-mobile-verificat-5ced3fb490225291 2026-09-13T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/global-in-vitro-antimicrobial-susceptibility-profiles-of-mycobacterium-abscessus-fa989aa6b0f056d5 2026-09-13T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/determinants-of-adverse-drug-reaction-reporting-for-antimalarial-medicines-a-mix-7f511f27b1f61e6c 2026-09-13T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/pre-surgical-immune-proteomic-profiles-in-serum-identify-inflamed-and-suppressed-4dc9fd98b8b9ad71 2026-09-13T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/bibliometric-analysis-of-clinical-trials-on-tobacco-use-and-mental-health-resear-6825e6a1bf36f0a8 2026-09-13T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/development-and-implementation-of-a-multi-attribute-quality-robustness-scoring-f-d6af0f220fb3e1dd 2026-09-13T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-impact-of-undiagnosed-child-adhd-on-family-outcomes-e35f9938b3a191a5 2026-09-13T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/meaning-centered-psychotherapy-for-existential-distress-and-demoralization-in-ad-0771ba15c32a9d1b 2026-09-13T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/quality-of-life-caregiver-burden-and-clinical-correlates-in-kabuki-syndrome-a-cr-4bd71d62b7107c31 2026-09-13T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/establishing-non-fasting-lipid-reference-intervals-and-clinical-decision-limits-f81e8304eb1fab70 2026-09-13T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/exploring-the-interplay-between-interoception-and-dissociative-experiences-insig-6419b2b230094dd4 2026-09-13T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/influence-of-gingival-thickness-on-clinical-outcomes-following-surgical-scalpel-1c459f18acc6a61b 2026-09-13T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-usability-of-an-explainable-ai-decision-support-tool-and-evaluation-of-f5c3a6def263501a 2026-09-13T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-efficacy-and-safety-of-celecoxib-for-postoperative-pain-in-major-orthopedic-c41f40b2e490fa69 2026-09-13T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/age-dependent-performance-of-conventional-trauma-scores-in-older-trauma-patients-df5cb966635b6338 2026-09-13T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/real-world-effectiveness-of-telitacicept-in-ebv-seropositive-patients-with-syste-fe93f7a17f0003a4 2026-09-13T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/multimodal-analysis-of-dental-radiographs-and-clinical-data-for-cardiovascular-r-13110790ce722d04 2026-09-13T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/construction-of-a-large-scale-biomedical-corpus-for-nlp-based-clinical-evidence-66d27e28a834d045 2026-09-13T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/prophylactic-home-based-exercises-during-radiotherapy-in-head-and-neck-cancer-a-22d5403dc9d4314f 2026-09-13T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-femoral-impingement-index-predicts-inferior-clinical-outcomes-in-men-undergo-d48f8a53f53a1bb0 2026-09-13T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-case-of-a-40-year-old-female-with-speech-disturbance-2192f4e6b9718ab9 2026-09-13T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/gc-biopharma-gets-phase-2-approval-for-covid-19-vaccine-bfab50deecd04760 2026-09-12T23:26:32.000Z weekly 0.7 https://www.pharmaradar360.com/article/samsung-bioepis-named-top-job-creating-company-eb946f6413a4e87a 2026-09-12T23:26:31.000Z weekly 0.7 https://www.pharmaradar360.com/article/gsk-s-adc-lays-down-marker-for-lung-cancer-scrap-with-merck-d370de291343afb9 2026-09-12T22:57:29.000Z weekly 0.7 https://www.pharmaradar360.com/article/veraxa-biotech-ag-stock-price-vrxa-stock-chart-market-cap-news-today-4961193ae7b32abd 2026-09-12T22:56:23.000Z weekly 0.7 https://www.pharmaradar360.com/article/eli-lilly-makes-another-biotech-bet-ahead-of-retatrutide-data-lly-stock-surges-t-f277b743c44c8524 2026-09-12T22:18:56.000Z weekly 0.7 https://www.pharmaradar360.com/article/adio-signs-strategic-deal-with-german-biotech-company-bayer-ac2bbec6d7c144ab 2026-09-12T22:02:13.000Z weekly 0.7 https://www.pharmaradar360.com/article/germantown-s-seraxis-announces-merger-to-form-diabetes-focused-biotech-company-040970b898a6533a 2026-09-12T22:00:27.000Z weekly 0.7 https://www.pharmaradar360.com/article/danish-pharmaceutical-novo-nordisk-introduces-ozempic-wegovy-drugs-in-kenya-eea7db5abbecd051 2026-09-12T21:12:54.000Z weekly 0.7 https://www.pharmaradar360.com/article/medpacto-trials-revive-deal-prospects-as-theragen-etex-weighs-holding-stake-chos-8c985c2657981640 2026-09-12T21:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/gc-wellbeing-bets-on-fat-shot-and-mounjaro-tie-up-to-drive-korea-growth-chosunbi-d96f47c9ea58eba2 2026-09-12T21:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/cancer-drug-hand-foot-syndrome-risks-mapped-in-huge-fda-analysis-238ae56f04af0703 2026-09-12T20:58:11.000Z weekly 0.7 https://www.pharmaradar360.com/article/pharmaceutical-speakers-the-complete-guide-to-find-book-hire-a-keynote-for-corpo-8a1ec198d20550d6 2026-09-12T20:33:06.000Z weekly 0.7 https://www.pharmaradar360.com/article/pharmaceutical-supply-chains-urged-to-begin-ndc-12-transition-planning-immediate-6e46cc9019edde23 2026-09-12T20:30:13.000Z weekly 0.7 https://www.pharmaradar360.com/article/trial-setback-might-change-the-case-for-investing-in-ultragenyx-stock-rare-3e2680d41502b831 2026-09-12T19:29:43.000Z weekly 0.7 https://www.pharmaradar360.com/article/why-your-ndc-12-roadmap-should-start-now-01536b53d86921d0 2026-09-12T19:29:05.000Z weekly 0.7 https://www.pharmaradar360.com/article/cms-s-hemp-cbd-program-has-a-physician-problem-mmj-appeal-pending-44ea6724fd164998 2026-09-12T19:23:17.000Z weekly 0.7 https://www.pharmaradar360.com/article/china-s-plan-to-leap-ahead-in-race-for-next-big-weight-loss-drug-f45ef54de9ee97d7 2026-09-12T19:11:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/donald-trump-talked-about-a-united-ireland-in-dublin-not-the-september-29-pharma-471e8e5510cb1b5f 2026-09-12T19:07:06.000Z weekly 0.7 https://www.pharmaradar360.com/article/outsourcing-formulation-activities-may-advance-drug-development-5944d75d5ad4da59 2026-09-12T18:04:21.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-cdc-confirm-cyclosporiasis-outbreak-linked-to-taylor-farms-lettuce-under-con-c3bf319fa3d66a29 2026-09-12T18:02:58.000Z weekly 0.7 https://www.pharmaradar360.com/article/how-direxion-daily-pharmaceutical-medical-bull-3x-shares-pill-affects-rotational-37342cd9f0425108 2026-09-12T18:02:02.000Z weekly 0.7 https://www.pharmaradar360.com/article/mumbai-news-live-updates-maharashtra-fda-crackdown-paneer-khoya-curd-butter-wort-e460d700b4c871ee 2026-09-12T17:56:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/rfk-jr-says-fda-will-act-on-petition-to-reexamine-some-ingredients-in-ultra-proc-612c000bde7480b5 2026-09-12T17:46:06.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-withdraws-publication-of-covid-shingles-vaccine-research-findings-0c9137b444e2e92a 2026-09-12T17:35:14.000Z weekly 0.7 https://www.pharmaradar360.com/article/federal-bill-would-give-fda-approved-botanical-drugs-12-years-of-market-exclusiv-e80660ca90099e5b 2026-09-12T17:23:50.000Z weekly 0.7 https://www.pharmaradar360.com/article/mbrx-stock-drops-25-as-moleculin-biotech-s-interim-cancer-trial-data-falls-short-d8f025f87aa6b36f 2026-09-12T17:12:35.000Z weekly 0.7 https://www.pharmaradar360.com/article/cathie-wood-s-biotech-bet-intellia-secured-an-fda-priority-review-for-rare-genet-5f7c852de259bb0e 2026-09-12T17:11:13.000Z weekly 0.7 https://www.pharmaradar360.com/article/etfs-investing-in-cabio-biotech-wuhan-co-ltd-class-a-stocks-a33d8632bf3d3697 2026-09-12T17:07:04.000Z weekly 0.7 https://www.pharmaradar360.com/article/ai-cyber-outer-space-biotech-critical-tech-shaping-opportunities-of-future-cbcbdcf9f3438d5c 2026-09-12T16:40:54.000Z weekly 0.7 https://www.pharmaradar360.com/article/sls-ibrx-eye-green-month-as-biotech-etf-gains-steam-analyst-sees-continued-oppor-6a1aa66cf3396998 2026-09-12T16:40:01.000Z weekly 0.7 https://www.pharmaradar360.com/article/phase-3-emerald-3-trial-stride-lenvatinib-plus-tace-in-embolization-eligible-hcc-d89f76dc4e0b7264 2026-09-12T16:27:47.000Z weekly 0.7 https://www.pharmaradar360.com/article/5-biotech-stocks-with-highly-anticipated-pending-results-685f8dc34535c878 2026-09-12T16:18:16.000Z weekly 0.7 https://www.pharmaradar360.com/article/promising-biotech-stocks-to-keep-an-eye-on-september-12th-efe64c7ece99109b 2026-09-12T16:07:30.000Z weekly 0.7 https://www.pharmaradar360.com/article/perioperative-immunotherapy-more-than-doubles-event-free-survival-in-early-stage-583f131177b9b417 2026-09-12T16:07:06.000Z weekly 0.7 https://www.pharmaradar360.com/article/cms-s-hemp-cbd-program-has-a-physician-problem-mmj-appeal-pending-7d101e291adc8983 2026-09-12T15:45:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/mumbai-ganesh-mandals-cancel-mahaprasad-over-fda-rules-15dff49a023b8fef 2026-09-12T15:11:53.000Z weekly 0.7 https://www.pharmaradar360.com/article/biotech-stocks-need-a-shot-in-the-arm-after-brutal-july-could-astrazeneca-bristo-0c28c1010a46e800 2026-09-12T14:36:31.000Z weekly 0.7 https://www.pharmaradar360.com/article/an-officer-may-come-and-go-but-a-trustworthy-institution-must-endure-says-tukara-a4fd43de647a7b40 2026-09-12T14:30:37.000Z weekly 0.7 https://www.pharmaradar360.com/article/this-small-cap-biotech-is-having-its-best-week-in-a-month-here-s-what-s-driving-681ea6d29eda7205 2026-09-12T14:26:18.000Z weekly 0.7 https://www.pharmaradar360.com/article/antibody-drug-conjugate-hits-recommended-phase-3-dose-in-egfr-mutated-lung-cance-2e7532b9f25e2b0c 2026-09-12T14:22:04.000Z weekly 0.7 https://www.pharmaradar360.com/article/strata-mental-health-solutions-receives-compass-pathways-grant-for-comp360-provi-5e7e3f29061c4e4e 2026-09-12T13:56:35.000Z weekly 0.7 https://www.pharmaradar360.com/article/maharashtra-fda-festive-crackdown-sweets-paneer-khoya-curd-butter-worth-rs-4-45-3758912ef772f17c 2026-09-12T13:48:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/can-fite-publishes-peer-reviewed-article-on-piclidenoson-and-namodenoson-potenti-0af5a6d68d575775 2026-09-12T13:47:44.000Z weekly 0.7 https://www.pharmaradar360.com/article/trump-drug-pricing-deals-and-policy-uncertainty-create-unreadable-market-landsca-049be17091ba1587 2026-09-12T13:36:49.000Z weekly 0.7 https://www.pharmaradar360.com/article/fundly-ai-raises-4-9-million-to-expand-b2b-pharma-platform-c50ea0daee21a08b 2026-09-12T13:14:42.000Z weekly 0.7 https://www.pharmaradar360.com/article/technical-analysis-of-state-street-spdr-s-p-biotech-etf-cryptocom-xbiusd-p-251011cd265c51ab 2026-09-12T13:06:29.000Z weekly 0.7 https://www.pharmaradar360.com/article/afghan-indian-officials-discuss-pharmaceutical-cooperation-b51c7c0a0b565719 2026-09-12T13:01:12.000Z weekly 0.7 https://www.pharmaradar360.com/article/evotec-stock-holds-near-52-week-low-as-revenue-drops-in-first-half-cef31d0bcd8eed64 2026-09-12T12:59:52.000Z weekly 0.7 https://www.pharmaradar360.com/article/b2b-pharma-platform-fundly-ai-raises-4-million-to-expand-commerce-payments-and-c-c143e24ddef24c12 2026-09-12T12:54:57.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-gras-rule-would-require-notice-not-additive-approval-91e1ec2ab4df24bb 2026-09-12T12:51:35.000Z weekly 0.7 https://www.pharmaradar360.com/article/abbvie-s-atogepant-delivers-positive-phase-3-results-in-menstrual-migraine-9b5b3859971b5d2e 2026-09-12T12:30:33.000Z weekly 0.7 https://www.pharmaradar360.com/article/should-debt-refinance-require-action-from-teva-teva-investors-85e0988c5562c871 2026-09-12T12:26:46.000Z weekly 0.7 https://www.pharmaradar360.com/article/uzbekistan-health-agency-partex-ai-to-develop-digital-solutions-9f48d894eef80e20 2026-09-12T12:15:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/india-joint-venture-partners-to-manufacture-pharmaceutical-products-in-moscow-ka-dc137a5820db4ea6 2026-09-12T12:03:03.000Z weekly 0.7 https://www.pharmaradar360.com/article/phase-1-study-supports-recommended-phase-3-dose-for-investigational-egfr-x-her3-9b4c556986e84b1d 2026-09-12T11:41:51.000Z weekly 0.7 https://www.pharmaradar360.com/article/uzbekistan-presents-pharmaceutical-products-in-south-korea-b84311811128667d 2026-09-12T11:30:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/astrazeneca-s-breast-cancer-drug-etcamah-fails-serena-4-trial-4c465fc11872fde1 2026-09-12T11:16:36.000Z weekly 0.7 https://www.pharmaradar360.com/article/zhu-baoguo-founder-of-taitai-oral-liquid-steps-down-as-chairman-of-two-chinese-l-33a6de160dc6d765 2026-09-12T10:35:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/azerbaijan-s-pharmaceutical-spending-rises-nearly-22-42364ddbd6b7dcf1 2026-09-12T10:32:15.000Z weekly 0.7 https://www.pharmaradar360.com/article/eu-court-adviser-backs-challenge-to-pharmaceutical-wastewater-charges-f5177be301b558f1 2026-09-12T09:38:09.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-warns-public-against-unregistered-tirzepatide-product-874e29e432742269 2026-09-12T09:24:03.000Z weekly 0.7 https://www.pharmaradar360.com/article/mesoblast-completes-phase-3-trial-dosing-for-chronic-back-pain-therapy-663a24f4517ade40 2026-09-12T09:09:21.000Z weekly 0.7 https://www.pharmaradar360.com/article/cyprus-tip-off-led-to-greek-raid-on-illegal-drug-laboratory-linked-to-mazonakis-5f9d99378c2c09f4 2026-09-12T09:04:24.000Z weekly 0.7 https://www.pharmaradar360.com/article/100-million-investment-plan-clears-way-for-bigger-pivot-park-176bf58aa84aed4b 2026-09-12T08:55:59.000Z weekly 0.7 https://www.pharmaradar360.com/article/advanced-breast-cancer-drug-fails-key-clinical-trial-days-after-regulatory-appro-098d437bd645687d 2026-09-12T08:50:01.000Z weekly 0.7 https://www.pharmaradar360.com/article/national-pension-service-acquires-112-357-shares-of-teva-pharmaceutical-industri-260337801488a062 2026-09-12T08:37:55.000Z weekly 0.7 https://www.pharmaradar360.com/article/fifth-circuit-panel-hears-case-on-restricting-mail-order-abortion-pill-507d815126a994ba 2026-09-12T08:30:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/is-west-pharmaceutical-services-wst-cheap-following-its-recent-run-up-9d80bd8465e3c4d8 2026-09-12T08:23:35.000Z weekly 0.7 https://www.pharmaradar360.com/article/comparing-healthcare-etfs-broad-vs-focused-exposure-516ea007c530dc21 2026-09-12T08:13:33.000Z weekly 0.7 https://www.pharmaradar360.com/article/relmada-s-ndv-01-bladder-cancer-trial-moves-into-phase-3-what-investors-should-w-6ae6a2ee7fa3d97e 2026-09-12T08:00:19.000Z weekly 0.7 https://www.pharmaradar360.com/article/pakistan-pharma-industry-medicine-prices-drug-supply-pharmaceutical-policy-aaj-n-12b516d606ae7852 2026-09-12T07:00:19.000Z weekly 0.7 https://www.pharmaradar360.com/article/pakistan-pharma-industry-medicine-prices-drug-supply-pharmaceutical-policy-aaj-n-ef0a623ac1e73cec 2026-09-12T07:00:16.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-raids-11-thane-farsan-manufacturers-seizes-food-stock-worth-20-48-lakh-b5b76e392e3e4591 2026-09-12T06:57:49.000Z weekly 0.7 https://www.pharmaradar360.com/article/top-14-pharma-stocks-to-buy-in-india-september-2026-1ca08eb69cc1f994 2026-09-12T06:51:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/jpmorgan-initiates-dianthus-stock-at-overweight-135-target-by-investing-com-eeff66b407baecfd 2026-09-12T06:49:04.000Z weekly 0.7 https://www.pharmaradar360.com/article/china-accepts-ncx-470-nda-for-review-in-glaucoma-treatment-cfc222df1edb77f1 2026-09-12T06:44:07.000Z weekly 0.7 https://www.pharmaradar360.com/article/pune-fda-registration-mandatory-for-ganesh-mandals-distributing-prasad-fb8b05dd2f28ecd1 2026-09-12T06:36:22.000Z weekly 0.7 https://www.pharmaradar360.com/article/thai-fda-reports-over-52m-baht-peptide-haul-on-september-11-a6e10730598338f8 2026-09-12T06:21:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/dftx-vs-cmps-which-stock-has-more-upside-from-trump-s-new-psychedelic-therapy-pu-ef64dcf5e3960581 2026-09-12T06:05:32.000Z weekly 0.7 https://www.pharmaradar360.com/article/illegal-weight-loss-products-worth-b50-million-seized-e7dc688eef2faddd 2026-09-12T05:02:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/south-korea-s-drug-agency-lags-behind-1960s-fda-d3716d4263c37159 2026-09-12T04:52:24.000Z weekly 0.7 https://www.pharmaradar360.com/article/cmps-stock-clocks-muted-gains-but-analysts-back-psychedelic-drug-s-durability-ah-6a4a3cae17e5d82c 2026-09-12T04:28:05.000Z weekly 0.7 https://www.pharmaradar360.com/article/frost-sullivan-presents-the-global-gene-therapy-crdmo-technology-innovation-lead-a3f7024e958c3afe 2026-09-12T04:25:03.000Z weekly 0.7 https://www.pharmaradar360.com/article/acquired-hemophilia-a-clinical-trial-pipeline-gains-momentum-c128454433b644e0 2026-09-12T04:18:04.000Z weekly 0.7 https://www.pharmaradar360.com/article/vietnam-vaccine-joint-stock-company-d68bb00762a34154 2026-09-12T04:17:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/tracing-and-technology-at-the-food-and-drug-administration-fbfa4ab87a9c4f5c 2026-09-12T04:09:36.000Z weekly 0.7 https://www.pharmaradar360.com/article/novartis-faces-a-reckoning-three-trial-failures-in-eight-days-test-the-limits-of-f4e0f13966bf3133 2026-09-12T03:50:49.000Z weekly 0.7 https://www.pharmaradar360.com/article/suspect-escapes-after-pursuit-following-drug-use-call-at-sequim-longhouse-6127b7b4572c5641 2026-09-12T03:38:13.000Z weekly 0.7 https://www.pharmaradar360.com/article/lady-gaga-and-michael-polansky-found-ai-biotech-company-77cc0d4530cd162b 2026-09-12T03:33:30.000Z weekly 0.7 https://www.pharmaradar360.com/article/k-bio-firms-make-trillion-won-bets-to-secure-overseas-new-drugs-jkn-8615c51b08db3bfa 2026-09-12T03:30:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/india-should-be-an-ai-powered-innovation-hub-and-not-just-a-low-cost-hub-dr-mahe-4c8e80ec418106a5 2026-09-12T03:29:59.000Z weekly 0.7 https://www.pharmaradar360.com/article/pune-fda-seizes-paneer-from-four-trucks-in-budhwar-peth-ahead-of-ganeshotsav-cel-e9086992498407f7 2026-09-12T03:04:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/journal-of-pharmaceutical-investigation-records-strong-citation-growth-with-5-5-690954f81d3094bf 2026-09-12T03:01:46.000Z weekly 0.7 https://www.pharmaradar360.com/article/abbv-stock-gains-on-winning-fda-approval-for-rare-blood-cancer-drug-1cabfd1aed67f747 2026-09-12T02:21:36.000Z weekly 0.7 https://www.pharmaradar360.com/article/genscript-biotech-1548-hk-synthetic-expert-call-transcript-11-sep-2026-de67dd4d07cf5638 2026-09-12T02:19:58.000Z weekly 0.7 https://www.pharmaradar360.com/article/pharmaceutical-company-expanding-adding-jobs-in-hauppauge-d80f5da0a5cd0868 2026-09-12T02:18:40.000Z weekly 0.7 https://www.pharmaradar360.com/article/hoth-s-pivot-from-biotech-to-space-tech-sparks-massive-rally-in-stock-retail-und-fea1a8d486dec34b 2026-09-12T01:58:22.000Z weekly 0.7 https://www.pharmaradar360.com/article/burning-rock-biotech-bnr-stock-rallies-while-losses-still-deepen-6fa40a99877d8199 2026-09-12T01:32:20.000Z weekly 0.7 https://www.pharmaradar360.com/article/biotech-startups-qualify-for-r-d-tax-credits-more-often-than-they-realize-k-38-c-99f5d2da9c4c0918 2026-09-12T01:20:02.000Z weekly 0.7 https://www.pharmaradar360.com/article/lilly-completes-ataibeckley-deal-adding-investigational-depression-pipeline-21206a1893121249 2026-09-12T01:00:53.000Z weekly 0.7 https://www.pharmaradar360.com/article/biomarin-pharmaceutical-bmrn-posts-phase-3-win-and-fda-filing-in-hypochondroplas-ddd070aa04ad5d21 2026-09-12T00:52:05.000Z weekly 0.7 https://www.pharmaradar360.com/article/new-bill-seeks-to-fix-drug-preclusion-provision-to-boost-dietary-supplement-inno-4a7fbbe7147f63f6 2026-09-12T00:04:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-mitochondrial-energetic-failures-in-men-and-women-across-trajectories-31cd531596d3e6fd 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-botswana-smoking-abstinence-reinforcement-trial-bsmart-b440b5808d9bca4b 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-enhancing-cervical-cancer-screening-and-treatment-in-women-living-with-572495050c5fa56d 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/advancing-clinical-trials-for-rare-renal-cell-carcinoma-subtypes-consensus-state-a87b4cb04bc0e94e 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/correlation-between-peak-expiratory-flow-rate-and-single-breath-count-in-patient-44cbb583fbb6fbdd 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/angina-bullosa-hemorrhagica-of-the-buccal-mucosa-a-diagnostic-challenge-in-an-or-c499811e3eb18f87 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/oral-myiasis-a-structured-review-of-risk-factors-clinical-presentation-and-treat-a135c68806420554 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/vitamin-d-dependent-rickets-type-1a-recognizing-clinical-clues-to-avoid-delayed-98e6b364df2a9e62 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-lightweight-hybrid-cnn-transformer-model-for-early-retinal-disease-screening-i-ebb3e4a15bbb9858 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/biblical-solutions-to-depression-a-critical-theological-pastoral-and-clinical-ex-769d167106a170c8 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/key-contamination-control-trends-identified-in-recent-fda-warning-letters-ec206a6030b88158 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/bactifind-an-offline-first-mobile-application-integrating-multiple-diagnostic-an-a90360d7fb045a26 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/evaluating-lstm-neural-networks-with-moving-average-features-for-short-term-stoc-2126b75c8d06bfc9 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/peer-review-report-for-improving-measurement-and-priorities-for-assessment-in-cl-0b36c70adde672df 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/phenotype-detection-of-biofilm-from-serratia-and-staphylococcus-aureus-isolated-e177cef720d9a902 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/147092de57e5fedc 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/how-public-health-and-clinical-workers-thought-about-climate-change-related-heal-db145f0e4a3b5085 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-and-anatomical-profile-of-patients-undergoing-cryoballoon-left-common-p-ba1b007a5bfe8cb3 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/comparative-analysis-of-the-cytokine-and-adipokine-profile-and-their-association-fce51a280cd65e62 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/preparation-of-highly-functionalized-lt-i-gt-ortho-lt-i-gt-naphthoquinone-methid-95395027a0c57261 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/highly-efficient-cellular-uptake-and-membrane-permeability-of-cell-penetrating-p-93591645586f0f0d 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-machine-learning-based-clinical-decision-support-system-developed-using-the-ni-dc6299db2e41b493 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/effects-of-combined-exercise-training-and-bicycle-ergonomic-adaptation-on-cyclin-9b7295e862750c9a 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/transcriptomic-profiling-of-paired-clinical-leishmania-mundinia-martiniquensis-i-b36bf486134862d1 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/targeting-the-dna-repair-chromatin-modifier-protein-smyd3-as-a-novel-epigenetics-cb63efdfe9501123 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-and-imaging-characteristics-of-cervical-ossification-of-the-posterior-l-73868998a7563784 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-randomized-controlled-trial-of-a-computer-based-intervention-to-increase-inter-e37187b75de3a1bc 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/relationship-between-the-oral-microbiome-and-post-surgery-aspiration-pneumonia-i-05661ba74407e6e7 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-and-radiological-outcomes-between-stemless-and-stemmed-anatomic-total-s-a760dfc92dc37bf5 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/prophylactic-administration-of-caffeine-reduces-bronchopulmonary-dysplasia-in-ve-d03f54d0dfedd103 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/model-construction-and-validation-of-dual-energy-ct-multi-parameters-combined-wi-54c3ed37fa0f89ab 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/oliceridine-versus-sufentanil-based-postoperative-pcia-after-orthopedic-fracture-55887b1a9cc29bb9 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/uncovering-drug-related-problems-in-hospitalised-cancer-patients-and-their-assoc-efc4570e5b32231c 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/emerging-of-i-bla-i-sub-ndm-5-sub-in-i-providencia-rettgeri-i-and-i-morganella-m-befc2442fad249cc 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/12-year-experience-with-rapid-pcr-for-carbapenemase-producing-enterobacteriaceae-d7ace291c1e0dd6d 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/sample-size-calculation-for-the-sequential-multiple-assignment-randomized-trial-b663246046ad92ac 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/translation-cultural-adaptation-and-validation-of-the-italian-food-allergy-quali-bf4cfc77b705b2e7 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-insufficient-publication-of-early-phase-clinical-trials-in-oncology-3892fd431663f8c1 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/safety-and-efficacy-of-i-lacticaseibacillus-rhamnosus-i-lra05-i-limosilactobacil-d6c57838e315bd89 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/serum-calcium-dynamics-and-risk-of-all-cause-hospitalization-and-mortality-in-he-1b56fc841056cc7c 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/antibiotic-timing-in-immunocompromised-patients-effective-therapy-as-one-piece-o-3e7e6c16bfba0086 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nucleotide-binding-oligomerization-domain-2-independent-colonization-by-i-turici-2670991088fd6e2d 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/formulation-and-systemic-therapy-a70251322316a57d 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/effects-of-positive-and-negative-peer-modelling-versus-neutral-social-interactio-b8eb188f4c130a5a 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/i-cyp2c19-i-genotype-guided-p2y12-inhibitor-therapy-optimization-in-patients-at-eaf494461dbb7efa 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/innovative-therapies-under-clinical-development-for-als-treatment-part-2-biologi-8f189a5884c96a74 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/effect-of-sensorimotor-training-on-pain-disability-kinesiophobia-and-quality-of-43617167d13bd661 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/plga-nanoparticles-co-loaded-with-resveratrol-and-doxycycline-for-dual-action-pe-939ca4ac398814e2 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-and-hematological-profiles-of-patients-with-burning-mouth-syndrome-acro-022457e51f90569e 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/body-composition-geography-and-ethnicity-understanding-the-associations-with-hea-83511d3ec99ead0c 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/osteoporosis-in-internal-medicine-outpatients-sex-specific-disparities-in-preval-be9fba067a2d76f0 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/multiple-drugs-79b281295c5b0029 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/laxatives-e366fbaab16cdd6e 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/lacosamide-trazodone-b8041cc37ac44beb 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/immune-globulin-34c51d4da30e4ce6 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/carbamazepine-4d56aaef213bd843 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/anabolic-steroids-19eb37cacfa42305 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/amfetamine-086d459f4e7fe4f2 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/antibody-drug-conjugate-related-pulmonary-aes-in-patients-with-lung-cancer-47aa3ae7f1966794 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/early-detection-and-intervention-in-at-risk-mental-states-rationale-structure-an-6929ea0ddf9d2682 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/improving-clinical-trial-design-in-low-back-pain-insights-from-studies-of-gabape-021af854b4928b1e 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/temporal-adaptive-transfer-learning-for-clinical-language-models-d7c2ca1be9632c5d 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-statistically-validated-ensemble-learning-framework-for-diabetes-prediction-us-2198a09ac2ef6a74 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/dentofacial-injuries-associated-with-e-scooter-use-a-narrative-review-of-the-int-25eb538c97f0ffca 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-outcomes-of-different-endoscopic-frontal-sinus-surgical-approaches-in-p-898283f0015f373f 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-course-and-treatment-outcomes-of-vulvar-condylomas-in-immunocompromised-6b3bbccb333263de 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/serum-nos1ap-concentration-association-with-clinical-polymorphism-of-schizophren-7ec98554276649f2 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-blended-learning-approach-to-online-dbt-skills-training-preliminary-clinical-o-47b9555f795b973d 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/comparative-genomics-reveals-genotype-phenotype-concordance-and-cryptic-resistom-623e614c1127a63a 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-rapid-molecular-detection-method-for-streptococcus-agalactiae-based-on-bacteri-46af29dbe8480bc6 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/histological-validation-of-barium-filled-vascular-channels-detected-by-high-reso-c3e6ce88dd5aaccb 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/behavioural-and-psychological-symptom-determinants-of-carer-burden-across-clinic-7864b1d2a21d3d14 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/in-vitro-approaches-for-modelling-gut-liver-crosstalk-in-drug-induced-liver-inju-62e7d0628aaa74b9 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/connective-tissue-graft-wall-technique-for-mandibular-class-ii-furcation-defects-abd37892f8f7e0d0 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/development-of-a-biorelevant-in-vitro-release-system-and-level-a-in-vitro-in-viv-9bf74a4eaa5cf8e2 2026-09-12T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/what-the-fda-s-new-psychedelic-framework-actually-means-for-the-clinic-82547d1a0aed17aa 2026-09-11T23:49:01.000Z weekly 0.7 https://www.pharmaradar360.com/article/scholar-rock-wins-fda-approval-for-first-drug-to-target-sma-muscle-loss-54ed2153766193cd 2026-09-11T23:33:54.000Z weekly 0.7 https://www.pharmaradar360.com/article/eli-lilly-completes-acquisition-of-ataibeckley-initiates-delisting-from-nasdaq-b-307af7d5f1d1afb4 2026-09-11T23:30:43.000Z weekly 0.7 https://www.pharmaradar360.com/article/drugging-the-undruggable-the-melbourne-biotech-taking-on-the-world-e50fad8ac922c69e 2026-09-11T22:24:11.000Z weekly 0.7 https://www.pharmaradar360.com/article/china-resources-sanjiu-medical-pharmaceutical-co-ltd-approves-interim-dividend-f-7f694037475f400a 2026-09-11T20:52:53.000Z weekly 0.7 https://www.pharmaradar360.com/article/china-resources-boya-bio-pharmaceutical-group-co-ltd-announces-board-changes-fbae6992f109587a 2026-09-11T20:51:20.000Z weekly 0.7 https://www.pharmaradar360.com/article/teva-pharmaceutical-announces-major-senior-notes-financing-61e3a7f427a0147b 2026-09-11T20:43:25.000Z weekly 0.7 https://www.pharmaradar360.com/article/could-tavapadon-change-parkinson-s-care-0b231a547acc5969 2026-09-11T20:40:55.000Z weekly 0.7 https://www.pharmaradar360.com/article/axios-live-research-and-manufacturing-investments-boost-philadelphia-s-biotech-r-7d5c80b74d9a41bd 2026-09-11T20:37:48.000Z weekly 0.7 https://www.pharmaradar360.com/article/exel-stock-slides-after-fda-adds-three-months-to-cancer-drug-review-william-blai-a4e0d321ec05963d 2026-09-11T20:19:17.000Z weekly 0.7 https://www.pharmaradar360.com/article/phase-3-summit-trial-tests-axs-05-for-smoking-cessation-c2a2ddb8654b9893 2026-09-11T20:12:09.000Z weekly 0.7 https://www.pharmaradar360.com/article/nanoscope-advances-gene-agnostic-therapy-for-severe-vision-loss-in-rp-a59d314d59074156 2026-09-11T20:07:51.000Z weekly 0.7 https://www.pharmaradar360.com/article/palatin-technologies-inc-common-stock-nasdaq-ptn-share-price-ptn-stock-news-ptn-56ba7f89d76a22c6 2026-09-11T20:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/west-pharmaceutical-stock-gains-after-insider-sale-and-strong-q2-figures-84d8fd9320071891 2026-09-11T19:52:05.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-extends-review-of-exelixis-drug-application-for-metastatic-colorectal-cancer-d62b22daff2084bc 2026-09-11T19:42:10.000Z weekly 0.7 https://www.pharmaradar360.com/article/anmat-emitio-una-carta-de-advertencia-a-csl-behring-s-a-por-incumplimientos-a-la-6974219701c6349a 2026-09-11T19:32:45.000Z weekly 0.7 https://www.pharmaradar360.com/article/assisted-dying-bill-defeated-in-house-of-commons-dd8a68cc3b3c1663 2026-09-11T19:07:51.000Z weekly 0.7 https://www.pharmaradar360.com/article/staunch-biotech-competition-spurs-new-secretive-tactics-shifts-investor-approach-bef2c24268292855 2026-09-11T19:07:21.000Z weekly 0.7 https://www.pharmaradar360.com/article/us-fda-extends-review-of-exelixis-cancer-drug-9bbcf3e5299b2c9a 2026-09-11T19:04:57.000Z weekly 0.7 https://www.pharmaradar360.com/article/takeda-bets-on-brazil-to-expand-dengue-vaccine-sales-4712091b388d5fff 2026-09-11T19:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/first-fda-approved-apds-treatment-for-kids-4-11-comes-from-pharming-group-n-v-ph-6045c809c3fc0ab8 2026-09-11T18:59:52.000Z weekly 0.7 https://www.pharmaradar360.com/article/thailand-seeks-pharma-deals-to-expand-medical-research-and-production-505d03828b78bd99 2026-09-11T18:52:37.000Z weekly 0.7 https://www.pharmaradar360.com/article/gout-pipeline-2026-fda-updates-therapy-innovations-and-clinical-trial-landscape-687f3aa04173aaa0 2026-09-11T18:34:52.000Z weekly 0.7 https://www.pharmaradar360.com/article/cordis-project-more-effectively-using-registries-to-support-patient-centered-reg-59f274e1114bf6a6 2026-09-11T18:34:10.000Z weekly 0.7 https://www.pharmaradar360.com/article/cordis-project-accelerating-drug-repurposing-for-rare-neurological-neurometaboli-c16144d3c82284b1 2026-09-11T18:32:11.000Z weekly 0.7 https://www.pharmaradar360.com/article/cordis-project-intranasal-rapid-acting-vaccine-for-all-seasonal-and-pandemic-inf-b7dc8c5747d85bdf 2026-09-11T18:32:03.000Z weekly 0.7 https://www.pharmaradar360.com/article/cordis-project-advancing-a-vaccine-targeting-genetic-amyotrophic-lateral-scleros-f895ba56b82d2329 2026-09-11T18:27:25.000Z weekly 0.7 https://www.pharmaradar360.com/article/cordis-project-a-personalized-prevention-roadmap-for-the-future-healthcare-1c2ab4d4a8f60b84 2026-09-11T18:27:15.000Z weekly 0.7 https://www.pharmaradar360.com/article/cordis-project-boosting-the-reduction-of-the-environmental-impact-of-pharmaceuti-82c038d6089768d0 2026-09-11T18:27:06.000Z weekly 0.7 https://www.pharmaradar360.com/article/opc-pharmaceutical-joint-stock-company-announces-change-in-certificate-of-busine-fe6de6c8360ed9ba 2026-09-11T18:21:55.000Z weekly 0.7 https://www.pharmaradar360.com/article/neonc-technologies-holdings-briacell-therapeutics-and-oncolytics-biotech-have-re-fc8f2dcdb12dee3b 2026-09-11T18:21:21.000Z weekly 0.7 https://www.pharmaradar360.com/article/healey-meets-with-biotech-startups-to-hear-about-financing-needs-d431d6eccb964475 2026-09-11T18:06:07.000Z weekly 0.7 https://www.pharmaradar360.com/article/exelixis-stock-slips-as-fda-delays-cancer-drug-review-analyst-weighs-in-05e0e8ddba9506b8 2026-09-11T18:02:50.000Z weekly 0.7 https://www.pharmaradar360.com/article/exelixis-stock-slips-as-fda-delays-cancer-drug-review-exelixis-nasdaq-exel-34a54ae1f51149f0 2026-09-11T18:02:50.000Z weekly 0.7 https://www.pharmaradar360.com/article/patients-already-in-biohaven-epilepsy-trials-keep-dosing-as-fda-pauses-new-enrol-62a9fc396951761c 2026-09-11T18:01:47.000Z weekly 0.7 https://www.pharmaradar360.com/article/ukrainian-pharma-exporters-urge-govt-to-establish-procedures-for-renewing-gmp-ce-1a18bf1597d22baf 2026-09-11T17:51:28.000Z weekly 0.7 https://www.pharmaradar360.com/article/leen-kawas-how-to-build-more-resilient-medicine-supply-chains-8d03a93b3e0cc9a0 2026-09-11T17:48:05.000Z weekly 0.7 https://www.pharmaradar360.com/article/cybin-cn-help-falls-5-91-as-clinical-stage-risk-and-phase-3-expectations-pressur-cdbe00e558c3223e 2026-09-11T17:38:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/top-biotech-picks-from-needham-company-for-second-half-of-2026-ee74fb0087d5cc48 2026-09-11T17:28:55.000Z weekly 0.7 https://www.pharmaradar360.com/article/gregg-gorniak-on-turning-dscsa-compliance-into-strategic-opportunity-b1bece38c56b9d17 2026-09-11T17:27:37.000Z weekly 0.7 https://www.pharmaradar360.com/article/could-this-new-opportunity-be-worth-billions-for-novo-nordisk-75f42972835db65c 2026-09-11T17:20:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/sartorius-stedim-stock-gains-support-as-q2-margins-hold-and-analysts-stay-positi-f53652650cff630f 2026-09-11T17:12:27.000Z weekly 0.7 https://www.pharmaradar360.com/article/freedom-broker-expects-a-correction-in-the-u-s-biotech-sector-2c9dd0505e15f6d0 2026-09-11T16:55:29.000Z weekly 0.7 https://www.pharmaradar360.com/article/system-secures-us-20-million-as-peptide-wellness-market-accelerates-10b30ecfaa2a980c 2026-09-11T16:53:23.000Z weekly 0.7 https://www.pharmaradar360.com/article/scancell-s-phase-3-melanoma-vaccine-trial-moves-toward-launch-raising-long-term-f055cd7f8d7dbdcf 2026-09-11T16:41:56.000Z weekly 0.7 https://www.pharmaradar360.com/article/why-patients-with-the-same-cancer-respond-differently-to-treatment-a60157c4a2114df7 2026-09-11T16:27:21.000Z weekly 0.7 https://www.pharmaradar360.com/article/weekly-buzz-jnj-wins-fda-nod-axgn-hcwb-strike-deals-roiv-azn-gpcr-lead-clinical-ee700ea0e8ab3089 2026-09-11T16:06:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/amgen-drops-10-on-a-trial-it-didn-t-even-run-2a676a36e7440c76 2026-09-11T16:05:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/psychedelics-are-on-the-fda-s-mind-098b13158b5d2c80 2026-09-11T16:04:32.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-extends-review-of-exelixis-colorectal-cancer-drug-candidate-2245083406727d54 2026-09-11T16:02:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/maharashtra-fda-suspends-199-eatery-licences-over-hygiene-7923dd3ae5553ace 2026-09-11T15:55:41.000Z weekly 0.7 https://www.pharmaradar360.com/article/clarity-on-ai-responsibilities-in-healthcare-needed-national-commission-says-9f92ea5d94637140 2026-09-11T15:52:10.000Z weekly 0.7 https://www.pharmaradar360.com/article/pharmtech-weekly-roundup-september-11-2026-86af1c68f7295979 2026-09-11T15:47:46.000Z weekly 0.7 https://www.pharmaradar360.com/article/new-fda-drug-approvals-august-2026-391a20e49e8f59a6 2026-09-11T15:45:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/pancreatic-cancer-drug-may-also-help-fight-treatment-resistant-lung-cancer-aafc03201b52ab40 2026-09-11T15:44:59.000Z weekly 0.7 https://www.pharmaradar360.com/article/gregg-gorniak-what-changed-in-five-years-of-dscsa-ca123a64e61f2012 2026-09-11T15:40:17.000Z weekly 0.7 https://www.pharmaradar360.com/article/simultaneous-anaerobic-bioreactor-could-accelerate-sustainable-biomanufacturing-ae1dbbfbb1b962fd 2026-09-11T15:36:09.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-grants-final-approval-to-cabozantinib-capsules-across-multiple-solid-tumor-i-5fa070859ffd2443 2026-09-11T15:33:56.000Z weekly 0.7 https://www.pharmaradar360.com/article/yarrow-brings-in-more-cash-abbvie-drug-succeeds-in-menstrual-migraine-trial-5b5adec38efa9e62 2026-09-11T15:28:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/duopharma-biotech-detects-unauthorised-system-access-attempt-01f83664a547773a 2026-09-11T15:27:06.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-grants-orphan-drug-status-to-lundbeck-s-asedebart-for-cushing-1eb4b1bc267f4c3f 2026-09-11T15:22:45.000Z weekly 0.7 https://www.pharmaradar360.com/article/news-by-cnbc-tv18-on-tradingview-2026-09-11-cnbctv-df10e080b094b-0-4a5c05ed391864b9 2026-09-11T15:17:33.000Z weekly 0.7 https://www.pharmaradar360.com/article/sex-ratios-at-birth-in-the-uk-2018-to-2022-7dbac71278ce6443 2026-09-11T15:09:30.000Z weekly 0.7 https://www.pharmaradar360.com/article/deep-learning-system-detects-lesions-in-sacroiliac-joints-576cfe05e4d10fd9 2026-09-11T15:01:50.000Z weekly 0.7 https://www.pharmaradar360.com/article/ptc-therapeutics-at-cantor-healthcare-conference-sephience-drives-growth-by-inve-b5e34fc199f16124 2026-09-11T14:48:57.000Z weekly 0.7 https://www.pharmaradar360.com/article/working-for-dhsc-7fde6c0568507ce7 2026-09-11T14:39:07.000Z weekly 0.7 https://www.pharmaradar360.com/article/decision-orphan-registered-medicinal-products-39e75e2ced1518f0 2026-09-11T14:20:39.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-expands-hyrnuo-use-in-her2-mutated-lung-cancer-c8473990dcc2cb27 2026-09-11T14:14:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/advanced-therapy-medicinal-products-regulation-and-licensing-in-uk-59aee4b062d03eb4 2026-09-11T14:11:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/why-pharma-s-next-ai-challenge-is-supervision-not-adoption-627d3deb812bd7dd 2026-09-11T14:09:06.000Z weekly 0.7 https://www.pharmaradar360.com/article/us-fda-extends-review-of-exelixis-cancer-drug-8757b11d14127d07 2026-09-11T14:05:18.000Z weekly 0.7 https://www.pharmaradar360.com/article/watch-conversations-on-america-s-global-biotech-leadership-0e8139d8aefabfa4 2026-09-11T14:04:23.000Z weekly 0.7 https://www.pharmaradar360.com/article/novartis-drags-peers-down-with-triple-asset-stumble-4768c8eda32578b3 2026-09-11T13:52:08.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-delays-approval-decision-for-exelixis-tyrosine-kinase-inhibitor-in-colorecta-ab8e72d19005bfd7 2026-09-11T13:52:01.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-future-of-ras-inhibitors-b9331991fc80225f 2026-09-11T13:48:47.000Z weekly 0.7 https://www.pharmaradar360.com/article/how-pharmaceutical-logistics-comes-together-d3a682022830edce 2026-09-11T13:47:07.000Z weekly 0.7 https://www.pharmaradar360.com/article/5-things-to-know-in-life-sciences-week-of-sept-7-2026-421ed658cac3010f 2026-09-11T13:45:39.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-extends-exelixis-zanzalintinib-review-by-three-months-pushing-decision-to-ma-71428bb12c3e3400 2026-09-11T13:45:04.000Z weekly 0.7 https://www.pharmaradar360.com/article/usfda-imposes-partial-clinical-hold-on-biohaven-s-epilepsy-drug-over-rodent-find-92a0f4f1b1601737 2026-09-11T13:43:13.000Z weekly 0.7 https://www.pharmaradar360.com/article/pneumococcal-disease-cases-caused-by-serotypes-not-covered-by-pcv13-ce6e5496ced9fd89 2026-09-11T13:42:47.000Z weekly 0.7 https://www.pharmaradar360.com/article/pneumococcal-disease-cases-caused-by-serotypes-covered-by-pcv13-2ddf38f53562a4bd 2026-09-11T13:42:16.000Z weekly 0.7 https://www.pharmaradar360.com/article/cancer-drug-shortages-keep-disrupting-patient-care-6e2e3af5fd0b345d 2026-09-11T13:41:13.000Z weekly 0.7 https://www.pharmaradar360.com/article/eli-lilly-completes-acquisition-of-ataibeckley-initiates-delisting-from-nasdaq-69f1dc69cfd406a7 2026-09-11T13:30:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/novo-holdings-and-leading-international-funds-are-investing-nearly-dkk-60m-in-a-7baec2cae950d5a3 2026-09-11T13:29:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/top-investor-urges-novartis-for-stronger-acquisition-oversight-after-m-a-and-tri-75168779bfdde9ca 2026-09-11T13:28:54.000Z weekly 0.7 https://www.pharmaradar360.com/article/us-fda-extends-review-of-exelixis-cancer-drug-97cc7bfefd52c9ea 2026-09-11T13:19:40.000Z weekly 0.7 https://www.pharmaradar360.com/article/ers-2026-bmi-type-2-inflammation-and-asthma-attack-risk-3aedc94d1f105ada 2026-09-11T13:08:06.000Z weekly 0.7 https://www.pharmaradar360.com/article/new-light-emitting-nanoparticles-can-detect-subtle-chemical-differences-to-enhan-67d29ed1f086abd0 2026-09-11T13:01:41.000Z weekly 0.7 https://www.pharmaradar360.com/article/lundbeck-drug-candidate-granted-another-us-fda-designation-9f040c75940d5b94 2026-09-11T13:00:53.000Z weekly 0.7 https://www.pharmaradar360.com/article/abbvie-s-atogepant-delivers-positive-phase-3-results-in-menstrual-migraine-b94ffc90724c6cb9 2026-09-11T13:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/astrazeneca-s-etcamah-falls-short-of-key-phase-iii-endpoint-in-breast-cancer-tri-5928c45ebac516f1 2026-09-11T13:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/14-l156-d-bio-organic-apple-peach-mango-6-months-lupilu-94ba913aacaf92bb 2026-09-11T12:52:25.000Z weekly 0.7 https://www.pharmaradar360.com/article/decision-medical-devices-given-exceptional-use-authorisations-550b955b3ef9248a 2026-09-11T12:39:47.000Z weekly 0.7 https://www.pharmaradar360.com/article/india-s-biotech-growth-needs-more-long-term-capital-says-expert-b0d7e83756aece93 2026-09-11T12:31:33.000Z weekly 0.7 https://www.pharmaradar360.com/article/this-week-in-science-poop-concrete-hot-ice-and-more-42a5bda2583b76a4 2026-09-11T12:30:31.000Z weekly 0.7 https://www.pharmaradar360.com/article/singapore-launches-biotech-focused-boston-hub-to-build-on-centuries-old-bond-b89995faef2f0ae8 2026-09-11T12:30:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/frazier-adds-1-1b-to-small-and-mid-sized-biotech-fund-ee5879e810cd4a42 2026-09-11T12:29:58.000Z weekly 0.7 https://www.pharmaradar360.com/article/kenya-s-wealthy-merali-family-acquires-stake-in-pharmaceutical-glass-plant-0ddbfae56327c1a6 2026-09-11T12:26:04.000Z weekly 0.7 https://www.pharmaradar360.com/article/eppendorf-launches-refrigerated-centrifuge-5811-r-aaa328684245d693 2026-09-11T12:19:54.000Z weekly 0.7 https://www.pharmaradar360.com/article/report-an-outbreak-of-acute-respiratory-infection-in-an-adult-social-care-settin-4b8ec42924935cd1 2026-09-11T12:14:06.000Z weekly 0.7 https://www.pharmaradar360.com/article/should-you-bet-big-on-drugmakers-vaneck-pharmaceutical-etf-vs-invesco-healthcare-6bf4962a35aab8ac 2026-09-11T12:13:54.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-download-biotech-s-future-and-cheaper-cleaner-steel-69a3d6cc2f2a0a2f 2026-09-11T12:10:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/sterlitech-launches-benchtop-membrane-filtration-systems-4c0ec37e526d2019 2026-09-11T12:03:57.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-extends-review-of-exelixis-drug-application-for-metastatic-colorectal-cancer-623f07bc4551e9d8 2026-09-11T12:01:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/profitable-biotech-incyte-forms-handle-as-institutional-buyers-load-up-on-stock-e395f7467425a742 2026-09-11T12:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/transition-of-the-icelandic-medicines-agency-s-website-in-full-swing-c750fd2961bf03e7 2026-09-11T11:59:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/mrna-cancer-vaccines-biggest-barriers-to-market-a1a5e5c1027f15da 2026-09-11T11:56:12.000Z weekly 0.7 https://www.pharmaradar360.com/article/u-s-fda-extends-review-of-exelixis-cancer-drug-deaffdf4f5a748a4 2026-09-11T11:49:56.000Z weekly 0.7 https://www.pharmaradar360.com/article/anmat-evaluo-y-libero-mas-de-430-lotes-de-vacunas-entre-junio-de-2025-y-mayo-de-379e0cb77fd0e730 2026-09-11T11:49:36.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-extends-review-timeline-for-exelixis-cancer-drug-19d15b23009bb8c7 2026-09-11T11:33:41.000Z weekly 0.7 https://www.pharmaradar360.com/article/frost-sullivan-presents-the-global-gene-therapy-crdmo-technology-innovation-lead-05419dc90ac4e4e3 2026-09-11T11:28:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/biohaven-s-epilepsy-drug-hit-with-fda-clinical-hold-115921639fbaab9b 2026-09-11T11:02:39.000Z weekly 0.7 https://www.pharmaradar360.com/article/how-investors-may-respond-to-sellas-life-sciences-group-sls-phase-3-trial-nears-36e1e2f8d7b894f7 2026-09-11T10:29:51.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-early-scale-cpc-biotech-and-multiply-labs-smoothen-cell-therapy-automation-b-cb9bcf29049b507a 2026-09-11T10:27:42.000Z weekly 0.7 https://www.pharmaradar360.com/article/shanghai-henlius-biotech-says-nda-for-120-mg-biosimilar-denosumab-hlx14-accepted-c33c1fb7dab637a0 2026-09-11T10:26:44.000Z weekly 0.7 https://www.pharmaradar360.com/article/mrkon-risks-explained-keytruda-dependence-patent-expiry-clinical-trials-and-toke-0f495729ddaa03b6 2026-09-11T10:21:13.000Z weekly 0.7 https://www.pharmaradar360.com/article/poland-s-case-against-eu-wastewater-rules-boosted-by-advocate-general-opinion-0cb3bd178f9e4c11 2026-09-11T10:18:25.000Z weekly 0.7 https://www.pharmaradar360.com/article/angelman-drug-partner-for-research-alliance-iii-racc-eyes-2029-data-6f76cf896ec6330e 2026-09-11T10:04:55.000Z weekly 0.7 https://www.pharmaradar360.com/article/estates-safety-fund-initial-schemes-and-associated-funding-allocations-2026-to-2-578511fd55580096 2026-09-11T09:54:19.000Z weekly 0.7 https://www.pharmaradar360.com/article/set-yourself-up-for-a-strong-2027-2-pharmaceutical-stocks-to-buy-in-september-7c5df69ea3cb3fa3 2026-09-11T09:53:27.000Z weekly 0.7 https://www.pharmaradar360.com/article/astrazeneca-shares-phase-3-results-for-imfinzi-plus-imdelltra-in-extensive-stage-bb2e83d5304d0724 2026-09-11T09:50:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/from-tartan-army-to-biotech-deepening-scotland-s-ties-with-boston-through-new-li-882a8830a7c1ede8 2026-09-11T09:40:13.000Z weekly 0.7 https://www.pharmaradar360.com/article/az-s-copd-drug-cuts-flare-ups-in-two-phase-3-trials-1e42b428339da8ba 2026-09-11T09:35:36.000Z weekly 0.7 https://www.pharmaradar360.com/article/set-yourself-up-for-a-strong-2027-2-pharmaceutical-stocks-to-buy-in-september-8cc69ed199f1afbf 2026-09-11T09:35:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/head-of-german-venture-fund-sees-big-potential-in-danish-biotech-but-investors-a-cbacdcd980c6a8e4 2026-09-11T09:35:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/are-you-working-with-the-non-clinical-package-for-clinical-trial-applications-se-381cb66138accd14 2026-09-11T09:34:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/rewriting-the-rules-of-genetic-medicine-with-trna-therapeutics-beyond-biotech-aee67803a2f832f6 2026-09-11T09:33:28.000Z weekly 0.7 https://www.pharmaradar360.com/article/trial-misses-prompt-shake-up-call-from-major-novartis-stockholder-9b04ea1f348cb183 2026-09-11T09:27:43.000Z weekly 0.7 https://www.pharmaradar360.com/article/what-regulators-ask-when-ai-touches-a-drug-application-601c189441f030a0 2026-09-11T09:27:43.000Z weekly 0.7 https://www.pharmaradar360.com/article/key-approvals-positive-study-results-and-a-partnership-deal-to-fast-track-new-me-4a3eb1cbd863abcd 2026-09-11T09:25:17.000Z weekly 0.7 https://www.pharmaradar360.com/article/shanghai-henlius-biotech-inc-announces-acceptance-of-new-drug-application-for-12-deaaab0cc42dfe4b 2026-09-11T09:20:41.000Z weekly 0.7 https://www.pharmaradar360.com/article/abbvie-drug-meets-phase-3-goal-in-menstrual-migraine-f35f3b3a549baf53 2026-09-11T09:00:32.000Z weekly 0.7 https://www.pharmaradar360.com/article/meet-the-under-35s-shaping-the-future-of-biotech-0e01cfbafd7d371b 2026-09-11T09:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/aprecia-pharmaceuticals-am-is-an-important-expansion-of-the-pharmaceutical-manuf-fa4992349a80da17 2026-09-11T08:51:35.000Z weekly 0.7 https://www.pharmaradar360.com/article/anavex-life-sciences-to-discuss-pediatric-inclusion-in-rett-syndrome-trial-by-in-b5f75a08654d2790 2026-09-11T08:49:55.000Z weekly 0.7 https://www.pharmaradar360.com/article/biotech-for-climate-resilience-fund-31985e360beccdf6 2026-09-11T08:43:27.000Z weekly 0.7 https://www.pharmaradar360.com/article/moderna-begins-phase-1-clinical-trial-of-ebola-vaccine-against-strain-behind-drc-0f15edae8af6e558 2026-09-11T08:26:58.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-advisers-narrowly-vote-to-add-6-peptides-to-a-drug-compounding-list-what-s-n-05eb0af1ede61b6f 2026-09-11T08:26:58.000Z weekly 0.7 https://www.pharmaradar360.com/article/reporter-s-notebook-k-biopharma-licensing-deals-are-getting-better-not-just-bigg-744ac6deb31a7e39 2026-09-11T08:24:18.000Z weekly 0.7 https://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-week-ending-13-september-2026-1016782b910b7d0c 2026-09-11T08:22:23.000Z weekly 0.7 https://www.pharmaradar360.com/article/astadaily-earns-purity-award-from-clean-label-project-d798f43275060d64 2026-09-11T08:20:36.000Z weekly 0.7 https://www.pharmaradar360.com/article/jpmorgan-initiates-dianthus-stock-at-overweight-135-target-76d704bda903e96f 2026-09-11T08:12:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/reporter-s-notebook-k-biopharma-licensing-deals-are-getting-better-not-just-bigg-c15b62c6b02b8567 2026-09-11T08:02:05.000Z weekly 0.7 https://www.pharmaradar360.com/article/biotech-students-must-step-out-of-comfort-zones-embrace-multiple-roles-suchitra-bd66bfb839665905 2026-09-11T07:57:14.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-clears-prelude-s-prt13722-phase-1-trial-in-hr-positive-breast-cancer-33a29eff5efb8a93 2026-09-11T07:33:49.000Z weekly 0.7 https://www.pharmaradar360.com/article/limitless-biotech-coupon-code-pct15-save-15-on-research-peptides-b07e64035e883a26 2026-09-11T07:22:22.000Z weekly 0.7 https://www.pharmaradar360.com/article/kenanga-launches-world-first-hang-seng-biotech-index-structured-warrants-258d523c61bb1937 2026-09-11T07:16:49.000Z weekly 0.7 https://www.pharmaradar360.com/article/marquis-who-s-who-honors-kenneth-hesterman-for-expertise-in-pharmaceutical-accou-4cd9960720360d81 2026-09-11T07:02:04.000Z weekly 0.7 https://www.pharmaradar360.com/article/pharmaceutical-excipients-market-to-reach-usd-24-88-billion-by-2035-at-8-1-cagr-e55ec71af1e14859 2026-09-11T06:57:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/velocity-clinical-stitch-expand-partnership-across-70-sites-to-boost-screening-a-e913a53837fd85f4 2026-09-11T06:48:46.000Z weekly 0.7 https://www.pharmaradar360.com/article/novartis-says-closely-watched-cholesterol-study-failed-to-meet-goal-c974947767e107ee 2026-09-11T06:45:32.000Z weekly 0.7 https://www.pharmaradar360.com/article/phase-3-study-shows-aqivc-superior-to-comparators-in-older-adults-b7ea1dfa91dfde4e 2026-09-11T06:38:44.000Z weekly 0.7 https://www.pharmaradar360.com/article/reg-rtw-biotech-opp-additional-investment-in-encoded-therapeutics-06ce266c777880ac 2026-09-11T06:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/orzeyful-approval-might-change-the-case-for-investing-in-takeda-stock-8b50302be3cb1bfe 2026-09-11T05:58:28.000Z weekly 0.7 https://www.pharmaradar360.com/article/what-strong-biotech-ip-strategies-get-right-and-where-weak-ones-break-down-a2b121fe65165341 2026-09-11T05:43:18.000Z weekly 0.7 https://www.pharmaradar360.com/article/comment-climate-change-threatens-pharmaceutical-companies-6987587302b518a2 2026-09-11T05:13:58.000Z weekly 0.7 https://www.pharmaradar360.com/article/henlius-86cc303c86469a6e 2026-09-11T05:10:44.000Z weekly 0.7 https://www.pharmaradar360.com/article/former-head-of-takeda-pharmaceutical-dies-at-80-6fc269c48465eb75 2026-09-11T05:03:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/active-biotech-ab-publ-sto-acti-is-breakeven-near-585e562e6ced9952 2026-09-11T04:30:06.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-partially-halts-trials-of-sk-biopharmaceuticals-epilepsy-drug-candidate-e77116af26fe1e1f 2026-09-11T04:17:50.000Z weekly 0.7 https://www.pharmaradar360.com/article/west-pharmaceutical-services-senior-vp-favorite-sells-2-77m-in-stock-9fe9896a7541d2cb 2026-09-11T04:16:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/jiangsu-handian-biotech-lands-tens-of-millions-of-yuan-in-strategic-round-89239b47de33a798 2026-09-11T04:01:52.000Z weekly 0.7 https://www.pharmaradar360.com/article/ex-takeda-pharmaceutical-head-hasegawa-dies-at-80-07ac3ad58f8939ed 2026-09-11T03:54:56.000Z weekly 0.7 https://www.pharmaradar360.com/article/paradigm-biopharmaceuticals-secures-additional-funding-for-phase-3-clinical-tria-54c8d0d78e14ca49 2026-09-11T03:19:09.000Z weekly 0.7 https://www.pharmaradar360.com/article/paradigm-biopharmaceuticals-asx-par-draws-final-us-2-million-tranche-as-phase-3-a44324072bfb26c8 2026-09-11T03:18:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-halts-sk-biopharm-s-opcalim-novartis-12-billion-drug-fails-phase-3-0ab09b28ac07fe98 2026-09-11T03:10:38.000Z weekly 0.7 https://www.pharmaradar360.com/article/paradigm-biopharmaceuticals-secures-additional-funding-for-phase-3-clinical-tria-ddb4fb8de8310392 2026-09-11T03:07:34.000Z weekly 0.7 https://www.pharmaradar360.com/article/laser-therapy-offers-new-hope-for-inoperable-pancreatic-tumors-aa7039f94cc04951 2026-09-11T03:01:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/viking-therapeutics-aims-high-at-92-target-but-clinical-risks-remain-cdae87387dc82248 2026-09-11T02:54:38.000Z weekly 0.7 https://www.pharmaradar360.com/article/data-aggregation-drives-ai-s-impact-on-clinical-supply-chains-c09c4abbac6eea8f 2026-09-11T02:41:32.000Z weekly 0.7 https://www.pharmaradar360.com/article/more-than-28-000-bottles-of-blood-pressure-drug-recalled-fda-11bf9d424e5e5c88 2026-09-11T02:31:59.000Z weekly 0.7 https://www.pharmaradar360.com/article/india-s-food-safety-crackdown-what-the-viral-raids-don-t-show-869bc1b6b56998d4 2026-09-11T02:08:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/agenda-for-november-2026-cancer-treatments-ctac-meeting-3a6d1f5f98e260f8 2026-09-11T02:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/frazier-life-sciences-adds-1-1b-to-biotech-public-fund-lifting-it-to-2-8b-e142f1ed47f39964 2026-09-11T01:48:06.000Z weekly 0.7 https://www.pharmaradar360.com/article/genscript-biotech-to-place-77-1-million-shares-at-hk-30-50-per-share-586a45444917dbb9 2026-09-11T01:29:44.000Z weekly 0.7 https://www.pharmaradar360.com/article/annual-iipa-debate-2026-ku-fda-plan-major-food-safety-awareness-push-in-j-k-415bf82849db4727 2026-09-11T01:24:57.000Z weekly 0.7 https://www.pharmaradar360.com/article/is-teva-pharmaceutical-industries-nyse-teva-still-a-bargain-or-fully-priced-22afb570e071b7c5 2026-09-11T01:16:33.000Z weekly 0.7 https://www.pharmaradar360.com/article/is-teva-pharmaceutical-industries-nyse-teva-still-a-bargain-or-fully-priced-a490fd25a3336a5e 2026-09-11T01:15:08.000Z weekly 0.7 https://www.pharmaradar360.com/article/exclusive-genencell-treatment-with-elevated-liver-enzymes-approved-for-clinical-775a5811d53df627 2026-09-11T01:11:03.000Z weekly 0.7 https://www.pharmaradar360.com/article/us-fda-pauses-new-enrollment-in-biohaven-s-epilepsy-drug-trials-f4e06e3e7cd27817 2026-09-11T01:05:11.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-places-hold-on-opacalim-trials-sk-biopharmaceuticals-says-limited-relevance-73bbabf1168b65b2 2026-09-11T00:38:39.000Z weekly 0.7 https://www.pharmaradar360.com/article/tukaram-mundhe-s-food-order-for-festivals-what-maharashtra-fda-commissioner-said-3dd813ddcd70dbc5 2026-09-11T00:10:17.000Z weekly 0.7 https://www.pharmaradar360.com/article/megazonecloud-begins-building-hanmi-pharmaceutical-s-quality-assurance-ai-agent-34906fa2a5c01536 2026-09-11T00:06:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/novo-nordisk-advances-new-injectable-obesity-drug-in-key-phase-3-trial-55906840ab9c4121 2026-09-11T00:01:48.000Z weekly 0.7 https://www.pharmaradar360.com/article/gsk-filed-form-6-k-130362fb32f7b414 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/national-heart-lung-and-blood-institute-notice-of-meeting-a3006d086a794e13 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/medical-devices-cardiovascular-devices-classification-of-the-cardiovascular-mach-212eaf111483ed36 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/agency-information-collection-activities-submission-for-omb-review-comment-reque-577ad723f444fe54 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/emran-mohammad-rn-aprn-cnp-decision-and-order-c222547fc36d6725 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/joseph-john-stubbers-iii-d-o-decision-and-order-56e3d57bd217be2e 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/cheryl-white-n-p-decision-and-order-6910fc9ec09361e7 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/craig-cohen-dpm-decision-and-order-bac086480e607f05 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/notice-of-supplemental-funding-appalachian-region-healthcare-support-program-eb7a15e20f6e765d 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/notice-of-supplemental-funding-infant-toddler-court-program-state-awards-556a097130f48a79 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/agency-information-collection-activities-proposed-collection-public-comment-requ-cbd46bd70ec39a02 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/amending-over-the-counter-monograph-m020-sunscreen-drug-products-for-over-the-co-bf1f21ba8881a138 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/agency-information-collection-activities-proposed-collection-comment-request-med-93720515e76d644f 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/agency-information-collection-activities-submission-for-office-of-management-and-c7cf00b962ad7623 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/notice-of-supplemental-funding-rural-hospital-stabilization-pilot-program-f42ef2358c137743 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/national-institute-on-aging-amended-notice-of-meeting-05a388dc6e88ab98 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/national-institute-of-diabetes-and-digestive-and-kidney-diseases-amended-notice-943f33d3924a19c8 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/center-for-scientific-review-notice-of-closed-meetings-e4c7ec9101c7b4ed 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-genetic-and-neuronal-mechanisms-that-regulate-zebrafish-sleep-13963d17da15b192 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-identifying-mechanisms-of-maternal-infant-obesity-risk-transmission-th-5231320863d40b50 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-physical-cellular-and-molecular-control-of-tissue-fission-and-fusion-04ca988f136f85e7 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-interplay-between-the-cellular-dna-damage-response-and-the-hpv-life-cy-11e4aa4c9fc5da58 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-air-pollution-and-well-being-assessing-risks-and-enhancing-education-i-ee55a9ff20a89d7f 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-transforming-systems-of-care-to-address-hiv-hiv-risk-and-substance-use-248d94971a013933 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-crcns-ecologically-realistic-perceptual-decision-making-0a71407f4b58d973 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-keyscope-the-key-to-sustainable-cancer-diagnosis-and-treatment-in-ugan-a4174514e3e0b43c 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-enhancing-cervical-cancer-screening-and-treatment-in-women-living-with-10047beacd58691e 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-consortium-for-advancing-management-and-prevention-of-cancer-in-people-892eb8de67da1184 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-revealing-proteoforms-the-driving-effectors-of-biological-function-2d464cb898bb03e1 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-systems-analysis-and-improvement-approach-to-optimize-the-cardiometabo-bad474e70a448c79 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-unraveling-the-roles-of-slc25a22-and-slc25a46-in-mitochondrial-metabol-e875aed539e1af27 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-treatment-of-health-complications-due-to-female-genital-mutilation-cut-05d8ea4c2011fd18 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-cellular-mechanisms-promoting-early-reactivation-of-latent-hiv-across-083341066da96588 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-influence-of-pregnancy-and-early-life-metabolome-and-lipidome-on-child-e8bde56982663740 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-change-sensitive-assessment-of-emotion-dysregulation-in-asd-across-the-ab37e17f67981468 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-advancing-exponential-family-random-graph-model-estimation-and-power-a-08a2eed8582c9695 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-innate-immune-cell-subtypes-involved-in-infant-responses-to-protein-co-0d97096435da2bfe 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-decoding-the-modified-small-rnas-that-drive-tlr7-8-mediated-neuroinfla-c06e5786963f87a6 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-mentoring-patient-oriented-research-to-individualize-care-for-hospital-c05b48e9767819b0 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-physiological-and-pathological-insights-into-trem2-ctf-cleavage-by-sec-06b7032c08c76925 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-joint-harmonization-of-structural-and-functional-connectivity-and-its-380b3d0cb2f0953d 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-mammalian-bile-acid-chemosensation-and-its-role-in-social-assessment-4fb20783373054c1 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-neuro-pasc-brain-fog-and-fatigue-is-caused-by-a-dysbiotic-gut-microbio-6f5074567336a61a 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-pi3k-pathways-in-molecular-selection-for-adjuvant-aspirin-treatment-of-56c348060631fb45 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-circadian-regulation-of-nutrient-metabolism-the-role-of-melatonin-in-p-92a5833570756147 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-analysis-of-longitudinal-multi-omics-data-for-prediction-of-preterm-bi-d02b1cdc35374778 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-therapeutic-development-to-target-tau-using-immunotherapy-and-crispr-b-454a655ce0a627b4 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-regulation-of-gut-lipid-metabolism-and-sexually-dimorphic-longevity-by-1c5696b9b3cd1dac 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-mitigating-the-renal-consequences-of-extreme-heat-in-older-adults-9f4efc5d28590b19 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-aligning-hospital-admission-decisions-with-health-priorities-of-people-a1c5e62744490229 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-a-pragmatic-randomized-controlled-trial-of-brief-meaning-centered-psyc-426c3af4d2b40a69 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-supporting-families-in-coping-with-parental-cancer-a-multi-site-random-bc1c70fc8f81b21b 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-p3-mechanisms-of-single-strand-break-repair-and-their-regulation-by-po-a9c644e0970c6d16 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-structural-cell-biology-of-dna-repair-machine-1c16bbc5d03ffe17 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-investigating-the-effects-of-increasing-o-glcnacylation-in-alzheimer-s-1a06e0a7f2449041 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-community-and-digital-technology-strategy-to-reduce-the-burden-of-hpv-e1ce3f3e95a1585b 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-dying-while-poor-investigating-multi-level-determinants-of-end-of-life-b4a3479d296e37cd 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-facilitation-of-information-exchange-for-shared-decision-making-for-lu-acac740f06a63d5f 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-personalizing-clinical-decision-support-for-heart-failure-treatment-to-692ae6600d5b8adf 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-an-intervention-to-reduce-cancer-associated-thrombosis-through-improve-312e90f62789b56a 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-estrogen-s-neuroprotective-effects-on-the-brain-barrier-in-restrictive-bf7a000e2783eecb 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-effect-of-rcr-healing-on-5y-clinical-outcomes-and-degenerative-shoulde-ae16c61c713aaa76 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-sch-ai-empowered-wearable-multimodal-sensors-ai-medallion-for-noninvas-341e0ad672592f92 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-evaluating-patient-performance-of-postoperative-incentive-spirometry-8ef170441db539e3 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-optical-modulation-of-quantum-nanomaterial-surface-chemistries-to-func-e8a2b03a3df418c9 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-hippocampal-precision-mapping-to-characterize-pathophysiology-in-amci-e243e5ed972c1d09 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-lrrk2-associated-mechanisms-of-granulovacuolar-degeneration-body-forma-4a9888fac6f80238 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-improving-alcohol-treatment-outcomes-for-women-across-the-lifespan-374ad0678f4bd97d 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-project-3-sex-differences-in-neurovascular-and-autonomic-regulation-pr-454d65063590db95 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-project-1-impact-of-prenatal-immune-dysregulation-on-sex-differences-i-ba1c72630a82d685 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-close-kin-mark-recapture-methods-to-characterize-suppression-of-aedes-520d9c237287b34a 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-role-of-the-ubiquitin-independent-proteasome-system-pathway-in-tau-deg-d7a3266a405559e2 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-adapting-and-pilot-testing-a-relationship-strengthening-intervention-t-1664af83108df395 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-molecular-pathogenesis-and-therapy-of-systemic-histiocytic-neoplasms-4f4c8166a8937ba0 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/study-shows-benefits-of-coffee-for-liver-health-db0567cadb2381ba 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-race-for-the-next-big-weight-loss-drug-is-on-and-china-wants-in-4ca0025474e6d592 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/effectiveness-and-safety-of-a-new-standardised-treatment-protocol-based-on-initi-e56b8bfccea093ab 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/sex-specific-efficacy-of-acetazolamide-for-acute-mountain-sickness-a-randomised-ee87c8ca10895aa3 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/what-services-do-people-seek-when-they-visit-a-community-pharmacy-care-clinic-d0b530ddc5e44386 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/managing-patients-with-heart-failure-a-contemporary-practice-tool-for-pharmacist-7c408d6b46d4237c 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/medication-safety-in-indigenous-communities-challenges-and-interventions-1bf49ca019f7d0e2 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/ten-year-analysis-of-publications-by-quebec-hospital-pharmacists-8f6c95173b5e694f 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-related-problems-in-older-adults-with-mild-cognitive-impairment-or-dementia-96f624acc8f4f4a9 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/management-of-a-patient-with-a-ticagrelor-rosuvastatin-interaction-an-algorithm-9d231ffd5b5bc159 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-call-for-the-generalist-pharmacist-bdb545612f6c918f 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/spinal-muscular-atrophy-biology-pathogenesis-and-therapeutic-advances-b415d007b404949e 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/herbal-extracts-and-plant-derived-bioactives-in-atopic-dermatitis-evidence-mecha-cd9cfcdb3b30d4c3 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/folfox-based-transarterial-infusion-chemotherapy-for-unresectable-colorectal-can-bea5551d37e257af 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/antibiotic-impregnated-bone-graft-to-prevent-infection-after-total-hip-arthropla-5268d85be60fdd94 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/pharmacokinetics-safety-and-exploratory-efficacy-of-onradivir-in-children-with-a-7df919b8089e655f 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/heiguteng-zhuifeng-huoluo-capsule-alleviates-osteoarthritis-associated-with-glyc-e816d5aada6daaeb 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/dose-optimization-of-deuruxolitinib-in-adults-with-alopecia-areata-a-phase-2-ran-732d8bf97a9e319a 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/efficacy-of-tdcs-primed-itbs-in-major-depressive-disorder-a-randomized-sham-cont-b40827847a532095 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/trastuzumab-botidotin-versus-trastuzumab-emtansine-in-human-epidermal-growth-fac-d39b584c172d264d 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/plasma-versus-whole-blood-tacrolimus-concentration-and-outcomes-after-kidney-tra-43fea2d7c00d92c0 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/late-onset-multiple-acyl-coa-dehydrogenase-deficiency-madd-glutaric-acidemia-typ-26ad462a8ff18b6e 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/benchmarking-drug-library-compliance-and-alert-rates-in-smart-infusion-pumps-a-m-cc042761c50bfb5e 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/successful-management-of-generalized-drug-influenced-gingival-enlargement-a-clin-a0dff0eeba02fdca 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-phenotypes-and-factors-associated-with-systemic-involvement-in-pediatri-bb23bbedc93d5e22 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-ictal-interictal-continuum-a-comprehensive-review-for-the-clinical-epileptol-1d28a0773cd7a283 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-impact-of-medical-procedure-in-needle-stick-injuries-among-healthcare-practi-a625c88de71da316 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/knowledge-attitudes-and-practices-regarding-hypertension-prevention-among-medica-95ce3ccfb7d13a35 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/acupuncture-care-for-a-patient-with-tennis-elbow-lateral-elbow-tendinopathy-a-ca-55448e3e6a6b64ce 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/i-ll-see-it-when-i-believe-it-73965d6ba86bbf24 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-practitioner-s-guide-to-ericksonian-choice-architecture-7ba5e46554ae733e 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/effectiveness-of-olfactory-training-and-topical-corticosteroids-for-persistent-p-284ef17782a9bce4 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/future-directions-b7312a04957ae1cb 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/teaching-the-invisible-a-game-based-simulation-for-learning-health-care-economic-7ea5cdfe5504fe20 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/pre-diagnostic-identification-of-cholestatic-liver-diseases-using-integrated-cli-89d880bf052825c6 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/chemical-fingerprinting-and-simultaneous-determination-of-main-compounds-combine-c618963982a18705 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/localization-of-advanced-drug-delivery-manufacturing-in-saudi-arabia-through-tec-a5d3d641a0ae9b7d 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/fused-spinopelvic-angle-in-adult-spinal-deformity-with-pure-sagittal-malalignmen-a50ebbefa1722eb4 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/predictive-analysis-of-social-determinants-of-health-in-posterior-cervical-spine-990d69caca0e348f 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/association-between-physical-therapy-and-mortality-in-older-patients-with-heart-9c687d7a8b736236 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/hydrus-microstent-combined-with-cataract-surgery-in-pseudoexfoliation-glaucoma-v-da281f09101151ea 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/functional-status-and-postoperative-outcomes-after-left-pancreatectomy-for-pancr-ece63d7def3a3618 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/diagnostic-approach-and-therapeutic-management-of-spontaneous-esophageal-perfora-729725021ca6e7c5 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-implementation-and-clinical-validation-of-a-whole-genome-sequencing-non-inva-5efd029892d9731c 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/risk-stratification-of-acute-symptomatic-anterior-circulation-intracranial-ather-060335b18fc361ee 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-clinical-study-of-simotang-oral-liquid-combined-with-shenque-acupoint-applicat-d4b5d7677424f285 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/fusion-level-selection-in-posterior-hemivertebra-resection-for-congenital-scolio-4356d58d5169b806 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/rethinking-ai-in-clinical-decision-support-a-framework-for-reciprocal-human-ai-i-1420c6c6866df483 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-efficacy-of-radix-arnebiae-oil-in-patients-undergoing-incision-and-drai-58f0e461772494f1 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/fetal-behavior-as-a-window-to-later-gross-motor-function-a-10-year-follow-up-of-c8f670e65987c96e 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-and-laboratory-criteria-for-a-differentiated-approach-to-the-management-d489377a752957d5 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/efficacy-of-dapagliflozin-in-the-treatment-of-patients-with-signs-of-cardio-rena-d4a6bb4196d21d84 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-rationale-for-individualizing-secondary-prevention-in-patients-with-ath-c7a775dd082043ba 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/edukasi-tentang-hoaks-obat-dan-kesehatan-di-media-sosial-dengan-bijak-berselanca-5fa5e8f4010bbf01 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-characteristics-and-surgical-outcomes-of-split-cord-malformations-a-ret-a259bf8535951c1f 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/evaluating-prevent-for-cardiokidney-outcomes-in-ckd-076f0a826668143c 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/executive-functions-and-conceptual-models-a-first-look-at-a-complex-topic-commen-237f2f36d13ca767 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/integrating-computed-tomography-and-magnetic-resonance-imaging-education-into-a-916bc317b1b11c9c 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/preparation-and-characterization-of-chitosan-co-acrylamide-hydrogels-for-control-6272337bb2bce876 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/enhancing-guideline-directed-medical-therapy-at-discharge-through-collaborative-61c425f8c65f8565 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-relevance-of-accuracy-in-in-house-3d-printing-in-craniomaxillofacial-su-5d29ff74d526eef8 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/effect-of-theory-based-health-education-intervention-in-improving-exclusive-brea-3c22484e4d298979 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/evaluation-of-the-feasibility-usability-and-preliminary-effects-of-an-mhealth-in-61c938230b152285 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-outcomes-of-cavaterm-thermal-balloon-endometrial-ablation-in-women-with-9a5696678c3b99a8 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/alveolar-ridge-preservation-using-advanced-platelet-rich-fibrin-versus-concentra-642458687bb7b17c 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/evaluating-the-therapeutic-efficacy-of-a-modified-ketogenic-diet-in-children-wit-7bdc14cebb6eaee3 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/effect-of-low-dose-esketamine-on-quality-of-recovery-after-gynecologic-laparosco-9565882e22d28941 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/salivary-lysozymes-anti-inflammatory-cardiac-medications-and-cardiovascular-mort-595fc7d8250f6e70 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-association-between-hormonal-contraceptives-and-lower-extremity-injuries-in-7f2bf0b2935043e0 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/uncertainty-and-novel-clinical-trial-designs-in-oncology-when-should-equipoise-m-9d09e54cf8511c76 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/from-discrimination-to-decision-external-validation-and-clinical-utility-of-a-di-fc08c4cab53491f2 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/oculomics-and-cardiovascular-disease-from-enthusiasm-to-clinical-reality-845c121fddcc7236 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/mitral-regurgitation-and-severe-aortic-stenosis-clinical-characteristics-prognos-56a6b86519668248 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/safety-and-efficacy-of-intratumoral-medi1191-an-il12-mrna-lipid-nanoparticle-plu-9feec652d62b5a63 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/spatiotemporal-mapping-of-tertiary-lymphoid-structure-heterogeneity-shapes-immun-b878c7a6750a845e 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/differentiation-between-bipolar-versus-unipolar-depression-by-ai-based-multimoda-10811a17d96af235 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/lignan-rich-norway-spruce-i-picea-abies-i-resin-extract-exhibits-anti-inflammato-bbbefd8591a7808a 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/alcohol-and-other-drug-policies-for-health-care-workplaces-evaluation-of-the-con-e99cec33373f8f7b 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/integrating-public-health-advertising-and-the-health-belief-model-to-predict-dia-a0939aee5e67c757 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/interesting-hurdles-in-the-solution-of-pharmaceutical-crystal-structures-using-p-3e514e35adab43a8 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/anterior-palpability-and-proptosis-as-clinical-predictors-of-ptosis-in-lacrimal-450fcdb8e69e20a6 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/what-factors-are-associated-with-shoulder-joint-pain-in-male-swimmers-including-2d4ac870140b4056 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/value-based-healthcare-scaling-value-based-care-through-surgeon-leadership-452cfb461f6acbc0 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/pro-ctcae-in-oncology-drug-evaluation-cross-agency-review-of-regulatory-and-heal-e2676d3716a504eb 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/strengthening-the-pre-hospital-chain-of-survival-for-out-of-hospital-cardiac-arr-95603fb884f8a5ca 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/optimized-dosing-of-momelotinib-in-myelofibrosis-through-quantitative-medicine-a-82759c408af8a2d1 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/implementing-structured-and-collaborative-clinical-planning-for-comprehensive-hi-2ee6f77428200007 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/from-daffodils-to-drug-leads-amaryllidaceae-alkaloids-target-protein-translation-d152f81dc448462f 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/maladaptive-movement-in-eating-disorders-clinical-correlates-and-cross-cultural-88f05d3f85a94292 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/gut-microecology-and-cardiovascular-disease-core-pathogenic-mechanisms-and-clini-3c2babc6119fff71 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/burnout-factors-for-pediatric-psychologists-across-career-stages-70a346964a211cd9 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/oligoclonal-band-count-as-a-marker-of-mri-lesion-burden-and-clinical-profile-in-750eee9cb00a292e 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-and-mri-features-associated-with-remission-following-biological-therapy-0d857f7086779929 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/repeated-perioperative-hypersensitivity-reactions-and-positive-challenge-testing-a6d40ff19fd054a0 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/safety-of-nonsteroidal-anti-inflammatory-drug-use-in-traumatic-brain-injury-579799c9f9af014a 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/pharmacokinetics-of-loading-dose-vigabatrin-administered-via-enteral-tube-in-par-90af192c98b082d8 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/responsible-implementation-of-ehr-based-clinical-prediction-models-beyond-perfor-eecda7cc2a55f5b8 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07816575-comparative-efficacy-of-alpha-hydroxy-acids-with-and-without-nanocar-d7ef75d6761b1a5d 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07816510-combination-of-oral-antifungal-treatment-for-refractory-dermatophyto-702068d4be42e1c4 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07816328-investigation-of-a-remibrutinib-and-omalizumab-based-treatment-algor-03dcb9b7e3a5e14f 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07815626-phase-3-study-to-evaluate-the-efficacy-and-safety-of-human-growth-ho-6269ee1ed4d7a47c 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07815301-gradual-tapering-or-discontinuation-of-beta-blockers-after-stabiliza-7fc2e5dc6cbb93d7 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07814365-pbi-for-low-risk-breast-cancer-a312bf3a7dc39711 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07813949-evaluation-of-clinical-performance-shade-matching-and-patient-satisf-7c074338dfdf4687 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07714538-breath-research-narrow-validation-for-gastrointestinal-cancer-detect-8b45a742a232789e 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07597746-effects-of-a-combined-repetitive-transcranial-magnetic-stimulation-a-8effc8546335d7ad 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07597161-trial-of-device-that-is-not-approved-or-cleared-by-the-u-s-fda-38094db28f64d38d 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07593079-prostate-specific-membrane-antigen-psma-imaging-for-detection-of-res-b3e776fd82076549 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07575685-enhancing-cancer-care-restoreme-app-for-personalized-nutrition-and-a-35ec302ac93c9811 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07566156-enfortumab-vedotin-in-combination-with-pembrolizumab-vs-concurrent-c-5e6eb7a3af17cfa1 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07557420-efficacy-safety-pharmacokinetics-pharmacodynamics-and-immunogenicity-d9d2b2f8a4ba8e14 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07489378-nci-childhood-cancer-data-initiative-ccdi-led-pediatric-adolescent-a-c53e59732f23426f 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07416786-validation-of-nad-measurements-for-human-clinical-studies-38d39bd6fb10bbc7 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07391774-testing-whether-hormone-therapy-with-ribociclib-is-as-effective-as-c-950c4ddcb9c97097 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07388537-evaluation-of-the-clinical-spectrum-of-diabetes-and-obesity-in-youth-3033397525ec41f9 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07370974-effect-of-clinical-hypnosis-in-preoperative-anxiety-among-patients-u-4cedb6dad168e6e8 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07278739-testing-an-educational-program-to-improve-goals-of-care-conversation-4133918c2dd23ca2 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07226349-a-study-of-bg-75098-alone-and-in-combination-with-other-agents-in-ad-60a0ce7404bbdbf3 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07103109-impact-of-proximal-motor-control-exercise-on-scapular-muscles-activa-602738f19bfdff82 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07091149-digital-cognitive-behavioral-treatment-of-insomnia-in-youth-an-rct-e-3868d1851c216b7b 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06921850-a-study-to-assess-the-pharmacokinetics-and-safety-of-bimekizumab-in-05eaad6aa11825f1 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06920511-cognitive-rehabilitation-with-virtual-reality-in-parkinson-disease-93602a996fb80ba0 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06899633-multicenter-observational-descriptive-study-of-the-diagnosis-course-0e77eb58f35b55e8 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06681662-ephedrine-for-reducing-onset-time-of-rocurinium-in-elderly-patients-b768979f5853708d 2026-09-11T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06562803-efficacy-and-safety-of-cytokine-adsorption-and-plasma-exchange-in-pa-06361ddfe1bd13c4 2026-09-11T00:00:00.000Z weekly 0.7